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Note to the readers 
 
Several years ago, when I was in the Physiotherapy Faculty, I had learned that the neural 
cell was the only one not able to regenerates itself. Today, this affirmative seems totally 
non-sense... Over the years I have seen massive scientific advances in the Neurology area. 
I still remember about a fantastic short video of electronic microscopy about the first 
studies of neuroplasticity and axonal sprouting when I was working as Physiotherapist in 
Brazil in 1999. A New Millennium was beginning and the research on Neurology and Brain 
studies had been starting an astonishing epoch at the modern medicine. In Portugal, more 
specifically in the Hospital Santa Maria, I had my first clinical experience with ALS patients 
which was very frustrating. Because as a Physiotherapist, our role is strongly linked to 
recovery the function in our patients and the exercise is our master key. But this does not 
happen with ALS/MND disease. The possibility of submitting an ALS patient to performing 
exercise was and still is seen as senseless approach and potentially harmful. However, 
recent scientific works have been presenting the role of exercise as a potential contributor 
for neuroprotection.  
In this Thesis, our main goals were to study the impact of an individualized exercise 
program on the functional decline and on the aerobic capacity in ALS; and assess the 
feasibility of a tele-monitoring for a home-exercise program that could help ALS patients to 
access a physiotherapy program to distance. As secondaries outcomes, we studied aspects 
related to management of the respiratory failure, the support for ALS caregivers, and 
disease progression in low resources settings.  
This dissertation is structured in 8 chapters: 
The first chapter of this thesis addressed a brief review about the clinical features of the 
disease and measurements of the functional decline. The Chapter 2 describe some aspects 
related to the prescription of exercise using Cardiopulmonary Exercise Testing (CPET). 
The main contributions are addressed in the chapter 3 and 4 respectively - through 2 
original articles, which describes the role of moderate aerobic exercise as determined by 
cardiopulmonary exercise testing (CPET) in ALS, and outcomes from a feasibility study 
about a tele-monitoring system to supervising home-based exercise in ALS.  
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Additional contributions are presented in the Chapter 5, 6 and 7, which are organized such 
as: 
The Chapter 5 is divided in 3 sections where we presented: 
• Section 5.1 - a brief review about Respiratory insufficiency in ALS, 
• Section 5.2 - the diversity on the management of the respiratory insufficiency in 
ALS,  
• Section 5.3 - the predictive value of the Non-Invasive ventilation settings and how 
this can influence the functionality and survival for ALS patients. 
In the chapter 6 are described outcomes from a feasibility study about an innovative pilot 
project performed with ALS caregivers about home management for this disease.  
The Chapter 7 present two originals research works about the disease progression in low 
resources settings, which are the first studies carried out with ALS patients in the African 
continent. 
Finally, the eighth and last chapter describe a general discussion and conclusions about the 
results presented in the previous chapters of this thesis, and prospects for the future. 
The research project aimed to study the role of exercise on the progression of amyotrophic 
lateral sclerosis and awarded a PhD Scholarship from the Foundation for Science and 
Technology (FCT - SFRH/BD/78413/2011). This work as well as all other studies included in 
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A Esclerose Lateral Amiotrófica (ELA) pertence a um grupo de doenças neurológicas 
conhecido como doenças do neurónio motor, as quais são caracterizadas por degeneração 
e morte progressiva dos neurónios motores. A doença manifesta-se por parésia progressiva 
e atrofia muscular, de início assimétrico,  com envolvimento de sucessivas regiões 
anatómicas durante a progressão da doença. Em geral, a doença inicia-se de uma de duas 
formas fundamentais: com envolvimento dos músculos da região bulbar; ou com perda de 
força muscular dos membros superiores ou inferiores – forma dita medular. Embora outras 
formas raras de manisfestação também sejam citadas na literatura, tais como:  respiratória  
(quando os músculos respiratórios são afectados inicialmente); axial (afecta inicialmente 
os músculos cervicais e paraespinhais) e a forma difusa (início generalizado da doença). 
Estas formas de apresentação determinam os sintomas iniciais. A progressão é variável. 
Algumas pessoas têm progressão lenta, enquanto outros têm uma rápida perda funcional. 
A perda de capacidade funcional condiciona dependência,  com progressiva necessidade 
de um cuidador para realização de todas as suas actividades de vida diária. 
A sobrevida média é de 3 - 5 anos desde os sintomas iniciais, e o evento fatal 
geralmente ocorre por insuficiência ou infeccção respiratória.  Apesar de não haver 
tratamento capaz de suster a progressão, a gestão clínica desta doença evoluiu 
positivamente nos últimos anos. Devido aos avanços tecnológicos das intervenções 
médicas, como a assistência respiratória (ventiladores portáteis, sistemas de tosse assistida 
e monitorização), medidas alternativas para alimentação e o uso das tecnologias de apoio 
à comunicação. O uso de telemedicina em algumas valências têm vindo a demonstrar 
resultadores animadores.  
Recentemente alguns estudos sugerem o exercício como potencial meio 
terapêutico, devido ao seu eventual efeito neuroprotector, descrito em alguns trabalhos. 
No entanto, o exercício aeróbico tem sido pouco estudado em doentes com ELA, devido ao 
receio de que o exercício possa ser prejudicial. Atendendo às recomendações da última 
revisão Cochrane sobre o exercício terapêutico na ELA, estudamos o impacto do exercício 
aeróbico na capacidade funcional e aeróbica dos doentes. 
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Os principais contributos desta tese foram: 1 - estudar a eficácia do exercício 
moderado e rigorosamente prescrito na evolução e sobrevida da ELA e, 2 -  a avaliação da 
possibilidade de exercitar estes pacientes com o controlo a distância.  O primeiro 
contributo está descrito no Capítulo 3, e estudou o impacto de um programa de exercícios 
baseado no teste de esforço cardiopulmonar sobre o declínio funcional e capacidade 
aeróbica dos doentes com ELA, num período de 6 meses.  Foram incluídos 48 pacientes 
divididos em 2 grupos: G1 (𝑛 = 24), no qual os doentes realizaram exercício com intensidade 
determinada pelo teste de esforço cardiopulmonar(TECP); e G2 (𝑛 = 24) como grupo 
controlo. Medidas de funcionalidade (usando ALSFRS-R) e avaliação da função respiratória 
(capacidade vital forçada – CVF) foram realizados a cada 3 meses; o teste de esforço 
cardiopulmonar foi realizado na admissão (𝑇1) e 6 meses depois (𝑇2). Foram registados o 
consumo de oxigénio máximo atingido (VO2pico), o dióxido de carbono exalado (VCO2) e 
Ventilação Minuto (VE) no limiar anaeróbico e no pico do esforço. Os resultados mostraram 
que em 𝑇1 ambos os grupos eram idênticos, excepto pelo maior valor de CVF no G1 (𝑝 = 
0,02). Em 𝑇2, o valor ALSFRS-R foi superior no G1 (𝑝 = 0,035). As variáveis 
cardiorespiratorias do TECP em 𝑇2 não sofreram alterações no G1, mas apresentaram 
diferenças significativas no G2 (𝑝 <0,05). Análises de regressão múltipla identificaram o 
exercício e o declínio funcional no score medular como predictores independentes da 
funcionalidade em T2. Com estes resultados, concluímos que um programa de exercícios 
aeróbicos baseado no teste de esforço cardiopulmonar é eficaz e pode trazer benefícios na 
ELA. 
O segundo contributo principal desta Tese é apresentado no Capítulo 4 e analisou 
a viabilidade da tele-monitorização de um programa domiciliar de exercícios determinado 
pelo teste de esforço cardiopulmonar, que poderia ajudar os pacientes com ELA a aceder 
um programa de fisioterapia a distância; tal como permitir o controlo do esforço físico, a 
aderência e os possíveis eventos adversos, pela equipe médica. Monitorizamos 10 
pacientes consecutivos com ELA durante 6 meses. Paciente e cuidadores consideraram o 
sistema de tele-monitorização de fácil utilização e a aderência foi excelente. A ausência de 
eventos adversos relevantes, e a monitorização contínua da frequência cardíaca e da 
saturação de oxigénio durante o exercício demonstraram que um programa domiciliar de 
exercício aeróbico moderado na ELA é clinicamente seguro. 
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Esta tese inclui também resultados de contributos secundários, os quais estão 
relacionados com relevantes questões problemáticas sempre presentes durante a 
progressão da doença tais como a gestão e abordagem da insuficiência respiratória (sub-
capítulos 5.2 e 5.3), o suporte aos cuidadores (capitulo 6 )e o potencial impacto de uma 
gestão clínica com escarsos recursos sobre a progressão da doença(Capitulo 7). 
No sub-capítulo 5.2 apresentamos um trabalho sobre a falta de consenso acerca do 
momento ideal para início da VNI e  sobre o uso de recursos alternativos no suporte 
respiratório.  Realçamos o impacto da VNI e da traqueostomia nos cuidadores familiares 
e/ou informais, em especial como pode potencialmente afectar a qualidade de vida. 
Reforça-se a importância da avaliação da capacidade emocional, física, social e psicológica 
do cuidador de forma a poder lidar com as crescentes necessidades de cuidado destes 
doentes. 
O sub-capítulo 5.3 apresenta resultados sobre a importância de uma gestão 
criteriosa no uso e configuração dos parâmetros da Ventilação Não-Invasiva (VNI), em 
particular o papel dos ajustes da ventilação e da aderência no declínio funcional e sobrevida 
dos doentes ventilados. Para tal foram analisados um vasto conjunto de dados registados 
a partir do software utilizado nos ventiladores, medidas de oximetria de pulso noturna e 
testes de função respiratória. Os nossos resultados sugerem que as variáveis que afetam o 
conforto respiratório do doente são relevantes para a aderência à VNI e afetam 
postivamente a sobrevida na ELA. 
O Capítulo 6 apresenta resultados de um estudo sobre a viabilidade de um 
programa de treino para cuidadores. A progressão incerta da doença e os cuidados a longo 
prazo, assim como o número insuficiente de profissionais de saúde especializados 
determinam  que a admissão desses doentes em hospitais ou em unidades de cuidados 
continuados seja uma opção complexa. Iniciativas que permitam uma melhor gestão da 
doença no domicílio podem ser uma solução alternativa. A incapacidade funcional dos 
doentes pode promover restrições financeiras significativas, e expõe as suas famílias a altos 
níveis de stress, os quais pode comprometer a prestação de cuidados de saúde adequados, 
levando à hospitalização destes pacientes. Neste projecto, identificamos um excelente 
nível de participação, bem como um bom resultado na avaliação da aprendizagem (acima 
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de 70%). O principal factor limitador à participação no programa de treino foi a ausência 
de um cuidador secundário.  
O Capitulo 7 descreve resultados de 2 estudos  realizados com doentes com ELA no 
continente Africano, os quais apresentam dados preliminares sobre a progressão da 
doença em um ambiente com recursos limitados para o sua gestão clínica. 
O Capitulo 8 apresenta uma discussão geral e conclusões sobre os trabalhos 
incluídos nesta tese, bem como algumas propostas de investigação para o futuro. 
Todos os trabalhos apresentados nesta tese pretenderam contribuir para uma visão 
mais alargada da gestão clínica da ELA, onde o papel do exercício associado a um suporte 
respiratório mais criterioso, e a presença de uma cuidador bem informado e treinado, 
possam em conjunto ser uma contribuição importante para a sobrevida e qualidade de vida 
do doente com ELA. 
Palavras-chave: Esclerose Lateral Amiotrófica, Ventilação Não-Invasiva, Exercício, 






Amyotrophic Lateral Sclerosis (ALS) belongs to a group of neurological disorders 
known as motor neuron diseases, which are caused by gradual degeneration and 
consequent death of motor neurons. In general, the disease begins in one of two 
fundamental ways: with involvement of the muscles of the bulbar region; or with loss of 
muscle strength of the upper or lower limbs - spinal form. Although other rare forms of 
manifestation are also cited in the literature, such as: respiratory (when respiratory 
muscles are initially affected); axial (initially affecting the cervical and paraspinal muscles) 
and the diffuse form (generalized onset of the disease). These forms of presentation 
determine the initial symptoms. Patients may initially develop muscle weakness in the 
limbs resulting in various clinical conditions with paresis, speech problems with dysarthria, 
dysphagia, and respiratory symptoms with dyspnea, and evolve to complete loss of body 
movements control. The degree of functional disability and dependence resulting from ALS 
lead the patient to gradually needing a caregiver for all their activities of daily life.  
The mean survival for ALS is around 3 - 5 years from first symptoms, and the fatal 
event usually occurs due to respiratory failure or infection. Although there is no effective 
treatment to halt disease progression, the clinical management has evolved positively in 
last years. The technological advance of medical interventions has contributed to a longer 
survival and higher quality of life. The monitoring of non-invasive ventilation has been very 
helpful for the clinical follow up and to decrease the anxiety experienced by caregivers. 
Unfortunately, the aerobic exercise is not a usual therapeutic option for ALS patients in the 
clinical management yet. 
Physical exercise has been suggested to promote growth factor delivery in 
experimental animal models of ALS. However, the aerobic exercise is understudied in ALS 
patients due the suspicious that the exercise could be harmful for this population. Meeting 
the recommendations from the last Cochrane review about Therapeutic exercise in ALS, 
we have analyzed the impact of aerobic exercise in the ALS progression. 
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This thesis has 2 main contributions: 1 - To study the efficacy of moderated and 
accurate defined exercise program on the evolution and survival of ALS, and, 2 - to assess 
the feasibility to performing exercise monitored remotely from home in ALS patients. 
In addition, this thesis includes results from additional contributions, which are 
related to relevant issues always present during disease progression such as management 
of the respiratory failure (sub-chapters 5.2 and 5.3), the support for ALS caregivers (Chapter 
6), and the potential impact of clinical management on disease progression in an 
environment with lack of resources (Chapter 7). 
In the sub-chapter 5.2 we present a work which describe the lack of consensus for 
the ideal timing to start NIV and about the use of alternative respiratory support. We 
address the impact of NIV and tracheostomy on family and / or informal caregivers, 
especially how it can affect quality of life. The importance of assessing the emotional, 
physical, social and psychological capacity of the caregiver is reinforced in order to cope 
with the increasing care needs of these patients. 
The sub-chapter 5.3 presents results on the importance of a careful management 
in the use and configuration of Non-Invasive Ventilation (NIV) parameters, in particular the 
role of ventilation and adherence adjustments in functional decline and survival of 
ventilated patients. A wide range of data recorded from the software used in ventilators, 
nocturnal pulse oximetry measurements and respiratory function tests were analyzed. Our 
results suggest that the variables that affect the respiratory comfort of the patient are 
relevant for adherence to NIV and positively affect survival in ALS. 
The Chapter 6 presents results of a feasibility study about a training program for 
caregivers. The uncertain progression of the disease and long-term care, as well as the 
insufficient number of skilled health professionals, determine that the admission of these 
patients to hospitals or to continuing care units is a complex option. Initiatives that allow 
better management of the disease at home can be an alternative solution. The functional 
disability of patients can promote significant financial constraints, and exposes their 
families to high levels of stress, which can compromise the provision of adequate health 
care, leading to the hospitalization of these patients. In this project, we identified an 
excellent level of participation as well as a good result in the evaluation of learning (above 
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70%). The main limiting factor for participation in the training program was the absence of 
a secondary caregiver. 
The Chapter 7 describes results from2 studies conducted with ALS patients in the 
African continent, which present data on disease progression in an environment with 
limited resources for clinical management. 
The Chapter 8 present a general discussion and conclusion of all works included in 
this Thesis. 
All the papers presented in this thesis aim to contribute to a broader view of the 
clinical management of ALS, where the role of exercise associated with more careful 
respiratory support, and the presence of a well-informed and trained caregiver, can 
together be an important contribution for the survival and quality of life of the patient with 
ALS. We hope our work presented in this thesis may contribute to a wider understanding 
on the clinical management of ALS. In particular demonstrating that controlled exercise 
associated with careful respiratory support, and the presence of a well-informed and 
trained caregiver, may be an added value in the survival and quality of life for ALS patient. 
















Chapter 1:  
Amyotrophic Lateral Sclerosis  




1. Amyotrophic Lateral Sclerosis - A brief review: 
1.1 Introduction 
 
Nowadays, the Amyotrophic Lateral Sclerosis (ALS) still is a condition extremely hard to 
define. It belongs to a cluster of clinical events that affects the motor neurons, known as 
Motor Neuron Diseases (MND). It is reasonable to say that ALS has the capacity to presents 
itself under different perspectives, dependent on who is analysing it. In a clinical 
perspective, ALS is seen as a progressive and pure motor syndrome combining upper and 
lower motor neuron involvement in multiple territories of the central nervous system 
(CNS), leading to death within a few years. A pathogenic vision describes ALS as a 
neurodegenerative disease, which the pathologic hallmark is the presence of ubiquitinated 
inclusions that stain with antibodies to the cellular protein TDP-43. The etiological point of 
view looks to ALS as a degenerative condition with a specific set of susceptible factors 
typically unmasked by ageing processes. From a biochemical perspective, ALS should be 
the consequence of one and/or all these events: excitotoxicity, oxidative stress, apoptosis, 
changes in axonal transport, calcium balance dysfunction, mitochondrial injury … etc. In the 
palliative care context, ALS is seen as a devastating terminal neurodegenerative disease 
with a highly unpredictable clinical course, hence palliative care follow-up should start soon 
after diagnosis (1). Scientifically, and due the significant advances that have been made 
about the understanding of MND pathogenesis, the researchers can describe ALS as a 
challenging complex disease involving an intricate combination of exogenous 
environmental factors and common and rare genetic variations (2), with a large phenotypic 
variability (3). 
On the ALS patients and caregivers’ point of view, the key words that would translate what 
ALS represent for them are: Loss and Adaptation. This disease affects not only the individual 
as well as it has catastrophic consequences on the family members. 
The last decade has seen major improvements in the patient care. The impact of new 
technologies and approaches for communication, as social networks, have helped to reveal 
more information about this rare neurodegenerative condition to the public in general and 
increased the opportunities for funding for research. 
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ALS has a type of presentation extremely heterogeneous, with an average of one-year delay 
from first symptoms to diagnosis, and subsequent unpredictable rate of clinical 
progression. This progressive disability with preservation of consciousness leads to death 
usually due to respiratory problems. Up to this year (2018) the Riluzol® was the only drug 
able to modify the disease natural history but statistically it only prolongs life around 3-6 
months (4,5). Recently, it was approved another drug called Edaravone® to be used with 
ALS patients in Japan, South Korea and United States. However, the benefits of this new 
drug still are unclear, since the primary outcome is not associated to a longer survival but 
with slight delay on the functional progression, without impact on respiratory function, 
which seems much less than the benefits from Riluzol®. Unluckily, drug administration and 
costs do not favor this new compound.  
In ALS, the respiratory insufficiency (RI) can occur in different clinical stages, and there is 
good clinical evidence indicating that Non-Invasive Ventilation (NIV) intervention plays a 
critical role in prolonging life (6). However, the motor rehabilitation approach to ALS 
patients require more studies about the potential role of exercise in this population (7). 
Many patients with ALS specifically ask whether they can continue or start exercising 
regularly without risk of accelerating their disease (8). But some studies suggesting that 
low-grade exercise programs can have some benefit (9). However, there is no solid 
evidence that exercise exerts a harmful effect, although avoidance of very strenuous 
activity seems reasonable (10). The role of exercise as neuroprotective factor is 
controversial still, some authors conjecture that it has a neurotrophic action promoting 
neuronal plasticity. To support the beneficial role of the exercise there are a few animal 
and clinical studies.   
In this dissertation, we studied the impact of a supervised aerobic exercise protocol on 
disease progression and the cardiorespiratory system of ALS patients, and evaluated the 
use of tele-monitoring system in ALS patients undergoing a home-based exercise program. 
Additionally, we presented results from other works related to: 1- management of 
respiratory insufficiency and its impact on the functional decline and survival in ALS 
patients, 2 – feasibility of training program for ALS caregivers, and 3 – Functional decline 
assessment and disease progression in low resources settings such as South Africa.  
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1.2 Clinical Characteristics: 
 
ALS is included in the heterogeneous group of neurological disorders characterized by 
degeneration of motor neurons (2), MND. The other four conditions are: Primary Lateral 
sclerosis (PLS), Progressive Muscular Atrophy (PMA), Progressive Bulbar Palsy (PBP) and 
Pseudobulbar Palsy (11). Around the world, ALS has received several different names, such 
as Motor Neuron Disease in United Kingdom, Lou Gherig Disease in USA and Charcot 
Disease in France (11). Nowadays, the public in general recognize the disease due the 
exposition of people diagnosed with ALS linked to artistic, scientific or sporty areas. The 
work developed in this thesis studied patients with ALS.   
Historically, there are two categories of presentation for ALS: sporadic and familial. 
However, the differences between familial and “apparently “sporadic ALS forms have not 
a defined and clear-cut boundary in the current genetic studies.  The recent advent of high-
throughput DNA sequencing instruments and exome wide gene capture tools has led to 
the identification of ALS linked variations in several additional genes (12). These advances 
have helped the understating on the polymorphous nature of the disease, and the 
ambiguity between sporadic and familial forms of ALS (13). The first known mutation linked 
to familial form was the SOD1 (Superoxide Dismutase 1) discovered in 1993(14). 
The discovery of the gene C9orf72 in 2011 changed radically the understanding of ALS 
pathogenesis and reinforced the concept of ALS as a multisystem complex disease. The 
C9orf72 (Chromosome 9 open reading frame 72) gene provides instructions for making a 
protein that is abundant in the neurons in the cerebral cortex and in motor neurons. This 
protein seems to influence the production of RNA and proteins and the transport of RNA 
within the cell. Some studies suggest that a probable alteration on the C9orf72 function 
can be linked to pathogenesis of the ALS (15).  
The diagnosis of C9orf72-related ALS/FTD is established by detection of a heterozygous 
pathogenic GGGGCC (G4C2) hexanucleotide repeat expansion in C9orf72 on molecular 
genetic testing (16). This hexanucleotide expansion is responsible for up to 10% of cases of 




C9orf72-related ALS/FTD is inherited in an autosomal dominant manner, with age-
dependent penetrance. Although most affected individuals have an affected parent, the 
parents may be unaffected because of either incomplete or age-dependent penetrance in 
the parent or a de novo pathogenic variant in the proband. Each child of an individual with 
C9orf72-related ALS/FTD has a 50% chance of inheriting the pathogenic C9orf72 G4C2 
hexanucleotide repeat expansion (16). 
Others recent mutations include Angiogenin, FUS, UBQLN2, C9ORF72 (19), and more 
recently NEK1 (20), which interacts with other proteins involved in neuron degeneration.  
Since early 2014, more than 20 genes had been identified as causative of, or highly 
associated with, ALS. Each of the seven novel genes (MATR3, CHCHD10, TBK1, TUBA4A, 
NEK1, C21orf2, and CCNF since 2014) code for proteins associated with one or more 
molecular pathways known to be involved in ALS, which include dysfunction in global 
protein homoeostasis resulting from abnormal protein aggregation or a defect in the 
protein clearance pathway, mitochondrial dysfunction, altered RNA metabolism, impaired 
cytoskeletal integrity, altered axonal transport dynamics, and DNA damage accumulation 
due to defective DNA repair(18). The figure 1 shows an impressive scenery about the 







Familial ALS cases constitute about 10% of all cases of ALS. Of this 10%, about 70% can be explained by genetics. 
Two substantial increases in genetic contribution to ALS were found in 2008 and 2011, corresponding to the 
identification of TARDBP (contributes to about 4% of familial and 1% of sporadic cases) and C9orf72 
(contributing to about 40% of familial cases and 8% of sporadic cases). ALS – Amyotrophic Lateral Sclerosis. 
GWAS – genome-wide association study. WGS – whole-genome sequencing. WES – whole-exome sequencing. 
NGS – next-generation sequencing. RP-PCR – repeated-primed polymerase chain reaction. SNP – single 
nucleotide polymorphism. ASO – antisense oligonucleotide. Ref. (18)  
Genes names – please, see list of genes in page 24. 
Figure 1. Genetic Landscape of ALS between 1993 and 2016  
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The advances in the ALS genetic research have been enormous since the last decade, 
however a comprehensive review that may describe the most recent findings about this 
thematic is out of scope of this Thesis. 
Although ALS usually starts in the fifth or sixth decade of life, an onset at almost any age 
has been described. Juvenile ALS is defined as ALS with age at onset before 25 years and 
the course of progression is generally slower than in other forms of ALS (21,22). 
The estimated lifetime risk of developing ALS for individuals aged 18 or older is 1/350 for 
men and 1/420 for women. The male gender, increasing age and hereditary disposition are 
the main risk factors (4,23,24).  
The ALS diagnosis is based on clinical history, examination, electromyography and exclusion 
of 'ALS-mimics' (e.g. cervical spondylotic myelopathies, multifocal motor neuropathy and 
Kennedy’s disease) through appropriated investigations (25,26). The most relevant clinical 
characteristic is the combination of upper and lower motor neuron clinical signs.  
At early stages, ALS presents a variety of signs and symptoms, making the diagnosis a hard 
task, which might take up to 12 months to be established (27). This disease affects, in a 
non-symmetric manner, muscles of the limbs, trunk and cranial nerves, with pyramidal 
signs, atrophy, fasciculation, fatigue and loss of strength. Usually, it progresses without 
alterations of other CNS pathways, namely the sensory tracts, cognition, coordination or 
sphincter function.  
Nichols and colleagues (28) suggests that clinical presentation and disease progression can 
be dependent of the location of initial symptom onset. Their work refers, for example, that 
the bulbar-onset results from upper motor neuron degeneration and includes spasticity, 
hyperreflexia, difficulty of swallowing, speaking or breathing due, at least in part, to 
degeneration of the corticospinal tract (29).  
The spinal-onset would produce characteristic signs of alpha motor neuron degeneration 
that include generalized muscle weakness, atrophy and fasciculation (29).  
As aforementioned, ALS can present a phenotypic variability regarding the pattern of motor 
involvement. Swinnen and Robberecht (2014) published a very informative review that 
should help to clarify this question (3). Figure 2 from their article summarizes the 
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phenotypes that can be found in clinical practice. The authors highlighted that the method 
and timing of assessment of a patient account for a considerable proportion of the clinical 
variability. Recent findings call attention to the role that interneurons may play in ALS 
























Pattern of motor involvement in  
different ALS phenotypes 
Figure 2. Pattern of motor involvement in different ALS phenotypes. Red indicates LMN 
involvement, blue indicates UMN involvement. Darker shading indicates more severe 
involvement. a | In spinal-onset ALS, patchy UMN and LMN involvement is observed in the 
all limbs. b | In bulbar-onset ALS, UMN and LMN involvement is observed in the bulbar 
muscles. c | In progressive muscular atrophy, LMNs in arms and legs are involved, often 
proximally. d | In primary lateral sclerosis, UMNs of arms and legs are primarily involved, 
but later in the disease, discrete LMN involvement can be detected. e | In 
pseudopolyneuritic ALS, only LMNs restricted to the distal limbs are involved. f | In 
hemiplegic ALS, unilateral UMN involvement with sparing of the face, and sometimes 
discrete LMN involvement, can be observed. g | In flail arm syndrome, LMN involvement is 
restricted to the upper limbs, but mild UMN signs can be detected in the legs. h | In flail leg 
syndrome, LMN involvement is restricted to the lower limbs, and is often asymmetric. 
Abbreviations: ALS, Amyotrophic Lateral Sclerosis; LMN, Lower Motor Neuron; UMN, Upper 
Motor Neuron. Adapted from [3]. 
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Although commonly known as a disease affecting motor function, there are variants that 
presents cognitive deficits, such as Fronto-Temporal Dementia (ALS-FTD). This is largely 
acknowledged in the literature and numerous studies show that primary deficits in ALS-FTD 
occur in attention and concentration, cognitive flexibility, word generation, problem 
solving and planning, abstract reasoning, visual and perceptual skills, fluency and memory 
(30).  
Controversially, there are few studies that report the presence of sensory (31) and 
autonomic dysfunction (32) during the progression of the disease. 
Unfortunately, the survival is an unpredictable question. The fatal event usually occurs 3-5 
years after the onset of symptoms, mostly linked to respiratory problems. A more detailed 
presentation about the Respiratory insufficiency in ALS is described in the Chapter 5, 
section 5.1 where we addressed aspects of the respiratory failure management. 
In the last years, main areas, such as respiratory care, management of swallowing and/or 
dysphagia problems and augmentative communication, stimulated a large interest. The 
constant improvement in the care service delivery associated with the use of modern 
alternatives health care solutions seems to contribute to increased survival. Nevertheless, 
monitoring the consequences of the disease process still requires an enormous ongoing 
effort from patients, their families, caregivers and health professionals. 
The next sub-chapter briefly describes the current tools used to measuring the disease 




1.3 Measurements of the disease progression and the functional impact: 
advantages and limitations 
 
The unpredictability of progression rate in ALS require repeated patient assessment to 
weight the impairment of motor and/or respiratory function, and their consequences on 
activities of everyday life. There are a variety of scales that can be used, and the choice of 
which one depends on the clinical objective.  The most known are: Norris scale, Appel ALS 
rating and the ALS Functional Rating Scale (ALSFRS). Most commonly used in ALS clinical 
trials include the Appel ALS rating and the ALSFRS (33). These scales are strongly correlated 
with patient survival (34).  
The total Appel score consists of five sub-scores: bulbar, respiratory, muscle strength and 
lower and upper extremity function. Each one is composed of individual tests. A group 
score of six points is assigned if there is no dysfunction and group scores of 30-36 points 
are assigned for maximal dysfunction. The total Appel ALS score is 30 for healthy subjects 
and 164 for those with maximum impairment (34). The rate of change in the Appel ALS 
Rating Scale is a significant predictor of survival for subjects with ALS (35).  
Another tool used is the Norris Scale that includes 28 clinical tests and six subjective 
evaluations (chewing, sphincter function and feeding) composing the evaluation of deficits 
and disabilities. Its main negative aspect is the weight given to upper limbs and under-
evaluation of respiratory function that might compromise the assess of the prognosis of 
patients (36).  Appel scale and Norris scale have been abandoned over time, due to their 
complexity and time necessary for application (33). 
Currently, ALSFRS-R is mostly used scale. It was originally known as Amyotrophic Lateral 
Sclerosis Functional Rating Scale (34) and covers four domains (gross motor tasks, fine 
motor tasks, bulbar functions, and respiratory functions). More recently it was revised to 
comply with the importance of respiratory function (35,37). The revised-ALSFRS (ALSFRS-
R) rates the ability to perform activities of daily living from 0 (total inability) to 4 points (no 
limitation) and incorporates respiratory items (dyspnea, orthopnea, respiratory 
insufficiency) (38). Although the ALSFRS-R seem to have a better balance between the 
domains, currently researchers are calling attention for some limitations of its use.  
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There are several publications that describes the efforts that have been done to improve 
the measurement of progression disease and highlight the need to develop a staging 
system that match with the observed progressive loss of independence or function. 
Rutkove (2015) refers that some of the disadvantages of this scale is the lack of sensitivity 
to progression in a short period of time and the effect of patient mood/effort on the scoring 
(39). Simon et al (2014) mentioned that one of the limitations of ALSFRS-R is the statistical 
manipulation required to handle data after death, and the clinical heterogeneity that 
distorts the link between total score and disease severity (40). 
The platform “Patients like Me” is a patient network and real-time research platform that 
connects patients who have the same disease and track and share their own experiences. 
It has developed an extension to ALSFRS-R, which was named the ALSFRS-EX. The main 
reason for this initiative was the observed “floor effect” when using ALSFRS-R. The proposal 
introduced three new items related to the ability to use fingers to manipulate devices, 
ability to show facial emotional expression and ability to get around inside the home. A 
validation is still necessary to assess the utility of the ALFRS-EX (41). Another aspect which 
have exposed limitation on the use of the ALSFRS-R is the lack of “no use “for the NIV for 
those patients in low and middle-income countries, with respiratory impairment but no 
using NIV due to socioeconomics or cultural reasons (42). Preliminaries results from a pilot 
study done are included in this work also, and it was presented in the 28th ALS international 
symposium in Boston, USA (2017). 
Despite these drawbacks, ALSFRS-R is the easiest and widely applied tool for research and 
routine clinical evaluation, able to measure the functional status in a single score.  
The next chapter address the importance of using cardiopulmonary exercise testing for 
exercise prescription. As ALS is a type of disease that affects the respiratory function over 
the time, we must specify carefully the workload that ALS patients should exercising 
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2. The use of Cardiopulmonary Exercise Testing for Exercise prescription 
 
This Chapter summarizes some important aspects about the use of Cardiopulmonary 
exercise testing for exercise prescription and recommendation for physical activity. The 
physical activity has a very well-defined role as contributor for a healthy lifestyle and the 
current literature is loaded with thousands of studies that reinforce the benefits on the 
mental health, cognitive performance, social behavior as well as on the functioning of the 
integrated different systems of our body.  
The dose-response relations detected in observational studies indicate that the more 
physical activity, the greater the health benefit. Results from experimental studies indicate 
that even modest amounts of physical activity can have health benefits in high-risk 
youngsters (e.g., obese). To achieve substantive health benefits, the physical activity should 
be of at least a moderate intensity (43). But physical activity and exercise are terms that 
describe different concepts. Physical activity in daily life can be categorized into 
occupational, sports, conditioning, household, or other activities. However, Caspersen in 
1985, defined exercise as a subset of physical activity that is planned, structured, and 
repetitive and has as a final or an intermediate objective the improvement or maintenance 
of physical fitness. Both terms often are confused with one another, and sometimes used 
interchangeably (44).  
The neuroprotective effect from exercise has been supported by studies related to 
Angiogenesis and Neurogenesis. Both issues present a strong link to neurodegeneration 
process. Recent evidences suggest that physical activity may be a reasonable and beneficial 
method to improve functional recovery from both peripheral and central nerve injuries and 
to delay functional decay in neurodegenerative diseases (45). However, exercising impose 
risks that increase its intensity, age, and in the presence of cardiorespiratory diseases or 
other diseases (46). 
In persons with neuromuscular disease that directly involves the cardiac and respiratory 
systems, deficits in performance may be primarily due to these limitations, along with loss 
of functional muscle tissue from the disease process. In the more slowly progressive 
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disorders, deconditioning may play an important role in limiting aerobic exercise 
performance (47). 
The category of moderate-intensity exercise refers to exercising at sub-maximal workloads, 
during which energy is supplied by the aerobic energy system. Exercising within this zone 
results in a host of physiological responses to the increased metabolic demand for oxygen 
by the skeletal muscle, skin, and brain. Prolonged training at moderate aerobic intensities 
results in physiological adaptations, including increased blood volume, capillary density, 
mitochondrial size and density, improved fat mobilization, and thermoregulation. 
Collectively these adaptations represent improved cardio-respiratory fitness. This fitness 
can be quantified by measuring the maximum rate at which an individual can take up and 
utilize oxygen, known as the “V˙O2 max” (43,48).  
A position statement published by Norton and colleagues (2010) (49) proposed the use of 
five categories (see table 1) to reflect groups of activities with similar relative physiological 



















Physical exercise requires the interaction of physiological control mechanisms to enable 
the cardiovascular and ventilatory systems to couple their behaviors to support their 
common function—that of meeting the increased respiratory demands (O2 consumption [ 
O2] and CO2 production [ CO2]) of the contracting muscles. Thus, both systems are stressed 
during exercise to meet the increased need for O2 by the contracting muscles and the 
removal of metabolic CO2. Therefore, by studying external respiration in response to 
exercise, it is possible to address the functional competence or “health” of the organ 
systems coupling external to cellular respiration (50).  
To identify a safe and individualized level to prescribe an exercise program for patients or 
suggest a physical activity for healthy individuals, we may use a non-invasive measurement 
of the cardiovascular and respiratory system called Cardio Pulmonary exercise testing 
(CPET). It is a provocative test that combines standard methods of electrocardiogram (ECG) 
stress testing with indices of gas exchange, which allows the investigator to distinguish 
Categories of exercise intensity and the subjective and objective measures [both absolute and relative] 
accompanying each category. The relative intensity measures such as % HR
max
, % HRR [Heart Rate Reserve = HR 
max
 − resting HR] and % VO2max [maximal oxygen uptake] will not always correspond to the same RPE (Rating 
Perceived Exertion) among individuals nor will the ability of clients to exercise for a specific duration at each 
intensity since this varies depending on training status and other personal characteristics. Subjective measures are 
from Borg’s RPE scales where C= category scale [6–20] and C-R = category-ratio scale [0–10] [49]. 
Table 1. categories of exercise intensity with subjective and objective measures from Norton and Colleagues 
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between a normal and an abnormal response characteristic of disease, grading the 
adequacy of the coupling mechanisms, and assess the effect of therapy on a diseased organ 
system (50). The exercise tolerance is determined by three factors: pulmonary gas 
exchange; cardiovascular performance, including the peripheral vascular tree; and skeletal 
muscle metabolism (51). It can be quantified clinically by measurement of oxygen uptake 
(VO2), carbon dioxide production (VCO2) and minute ventilation (VE). These parameters are 
measured during exercise with rapidly responding gas analyzers capable of breath-by-
breath determination of O2 and CO2 concentrations (52).  The table 2 presents the most 
used variables to be integrated as part of a CPET assessment. 
 
Table 2.  Key Ventilatory variables to be integrated as part of a CPET assessment 
VO2peak – Oxygen utilization (mLO2.Kg-1.min-1): A measure of aerobic capacity. 
VT: VO2 at the ventilatory threshold (mLO2.Kg-1.min-1): a measure of submaximal exercise tolerance. 
RER: Respiratory Exchange Ratio: the ratio of exhaled CO2 to inhaled O2. Provide a means to quantify 
subject effort during the CPET. An RER ≥ 1.00 indicates good effort and RER ≥ 1.10 indicates excellent effort. 
VO2/w (mL/min/w): Characterizes the ability of exercising muscle to extract oxygen. A low VO2/w 
relationship suggest cardiac or pulmonary impairment. 
O2 pulse (mL O2/heart beat): approximates stroke volume. 
PetCo2: End-tidal CO2 or the level of CO2 in the air exhaled from the body (measured in mmHg). Reduced 
values indicate VQ mismatching and is consistent with worsening cardiac or pulmonary disease severity, 
and worse prognosis. 
VE (L O2 /min): Minute Ventilation (based on tidal volume and respiratory rate) during the exercise. Peak 
VE can help to determine if the exercise tolerance or dyspnea relate to a pulmonary limitation.  
VE/MVV: Assessment of the maximum minute ventilation during exercise relative to maximum voluntary 
ventilation which is determined during the Pulmonary Function Tests at rest. The VE/MVV ratio is normally 
≤ 80% (and consistent with the premise that the pulmonary system is not limiting the exercise capacity); a 
ratio > 80% suggests pulmonary limitation. 
VE/VCO2 slope: Measurement of ventilatory efficiency (i.e. minute ventilation relative to CO2 exhalation). 
Whereas VE/VCO2 slope is normally < 30, efficiency decreases with Heart Failure, intrinsic lung disease, 
and/or pulmonary hypertension.  
Exercise oscillatory ventilation: Oscillation ventilatory pattern that indicates poor prognosis in patients 
with heart failure 
Pulse Oximetry (% O2 Saturation): Decline in hemoglobin excess oxygenation levels < 90% indicative of 
diminished ability to adequately increase alveolar-pulmonary capillary oxygen transfer during exercise. 




The choice of parameters to be considered will depend on the indication to 
cardiopulmonary exercise testing in the individual subject or patient, namely, exercise 
tolerance assessment, prognostic stratification, training prescription, treatment efficacy 
evaluation, diagnosis of causes of unexplained exercise tolerance reduction, or exercise 
(patho)physiology evaluation for research purposes (54). 
It follows a brief description about some of the most often parameters assessed in the 
CPET: 
Oxygen Uptake ( VO2): 
It is the volume of O2 extracted from the air inhaled during pulmonary ventilation in a 
period. It is usually expressed in mL.min-1 or L.min-1(Standard Temperature and Pressure 
Dry - STPD). Factors that can influence O2 availability are oxygen-carrying capacity of the 
blood (available hemoglobin, arterial O2 saturation, and dissociation curve shifts with 
temperature, CO2, and pH), cardiac function (Heart Rate, stroke volume), redistribution of 
peripheral blood flow, and extraction by the tissues (capillarity density, mitochondrial 
density and function, adequacy of perfusion, and tissue diffusion) (55). 
VO2peak and VO2max: 
VO2max (Maximal oxygen uptake) was defined by Hill and Lupton in 1923 as the oxygen 
uptake attained during maximal exercise intensity that could not be increased despite 
further intensifications in exercise workload, thereby defining the limits of the 
cardiorespiratory system (56). In the practice, maximum VO2 ( VO2max) is defined as the 
highest value reached, despite progressive increase of the load applied, with the 
development of a plateau in the VO2 curve during an incremental exercise test.  
When no plateau can be identified, the highest value obtained at the end of an exhausting 
exercise is characterized as peak VO2, which, in practice, is used as VO2max (see example in 
the figure 3). The response is influenced by a central mechanism (cardiovascular and/or 
pulmonary) and peripheral function (skeletal muscle). The normal values depend on several 
factors, such as: age, gender, weight, height, physical activity level, genetic variability and 






Figure 3. Example of a graph to identifying the VO2 peak (58).  Note: HF – Heart Failure 
 
 
Carbon Dioxide Production ( VCO2): 
Refers to the amount of carbon dioxide exhaled from the body per unit time. It is expressed 
in ml/min and its value increases with progressive exercise. It continues to rise after the 
completion of exercise as the muscles continue to eliminate carbon dioxide before 
returning to baseline levels after several minutes. VCO2 during exercise is determined by 
similar factors to those that govern O2 uptake: cardiac output, CO2-carrying capacity of the 
blood, and tissue exchange (55). 
Anaerobic Threshold (AT): 
The ATS/ACCP statement (55) presents different nomenclature for the anaerobic threshold, 
such as:  the lactate threshold, lactic acid threshold, gas exchange threshold, or ventilatory 
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threshold. The Anaerobic threshold – one of the most used term - is considered an 
estimator of the onset of metabolic acidosis caused predominantly by the increase rate of 
rise of arterial [lactate] during the exercise.  
Alternatively, the term lactic acid threshold and Ventilatory threshold are used also, but 
the former should be applied only when Lactate is directly measured from blood samples. 
The latter one implies that a ventilatory response has occurred and that is due to metabolic 
acidosis, although the two may not be causally related (55). The AT is associated to changes 
in gas exchange in the lungs through the exercise. 
 During the initial (aerobic) phase of CPET, which lasts until 50–60% of VO2max is reached, 
expired ventilation (VE) increases linearly with VO2 and reflects aerobically the produced 
CO2 in the muscles. Blood lactate levels do not change substantially during this phase, since 
muscle lactic acid production is minimal (51). The anaerobic threshold appears at about 
two-thirds of the way through a good maximal effort (See figure 4). In response to the 
progressive metabolic acidosis that develops during a normal maximal effort, we observe 
a compensatory increase in minute ventilation. Identifying whether this threshold is 
present is a critical part of test interpretation. 
 There are several ventilatory parameters which have been utilized in assessing ventilatory 
threshold, among which are oxygen consumption (VO2), pulmonary ventilation (VE) 
respiratory exchange ratio (RER), excretion of CO2 (VCO2), and the ratio of ventilation to 
oxygen consumption (VE / VO2). Due its easy application, one of most used method to identify 





Figure 4. Identifying the Ventilatory Anaerobic Threshold (58). The anaerobic threshold is the point 
at which the slope of the relative rate of increase in VCO2 relative to VO2 changes. 
 
Respiratory Exchange Ratio (RER):  
Refers to the ratio of carbon dioxide production to oxygen consumption (VCO2/VO2). Under 
steady state conditions, the RER equals to respiratory quotient (RQ), whose value is 
determined by the fuels used for metabolic process. An RQ of 1.0 indicates metabolism of 
primarily carbohydrates, whereas an RQ of less than 1.0 indicates a mixture of 
carbohydrates with fat (RQ about 0.7) or protein (RQ about 0.8). At rest in normal 
individuals, the RER value will be around 0.8.  
The term ”RQ” is often reserved for expressing events at the tissue level, which is difficult 
to measure and is not determined during the clinical exercise testing. The term ”RER”  is 





Ventilatory Efficiency (VE/ VCO2): 
Ventilatory efficiency describe the efficiency of pulmonary clearance of CO2 during the 
exercise and reflects the match of the pulmonary ventilation to perfusion. The normal 
response of the VE/ VCO2 slope or submaximal ratio expressions are both typically < 30. In 
the clinical practice, the VE/ VCO2 is used as an index of disease severity in certain chronic 
populations (59). Figure 5 shows an example of assessment of VE/ VCO2. 
 
Figure 5. Assessment of VE/VCO2 slope in healthy control (athlete) compared to patients with mild and 
moderate Heart Failure (HF) (58) 
 
Exercise Oscillatory Ventilation: 
Exercise oscillatory ventilation (also sometimes referred to as exercise oscillatory 
breathing) is the exercise equivalent of Cheyne-Stokes respirations, in which there are 
significant oscillations in ventilation that persist through greater than 60% of the exercise 






Figure 6. Assessment of Exercise Oscillatory Ventilation. A) Normal, linear, ventilatory response. B) Exercise 
oscillatory ventilation (58). Legend: BTPS, Body Temperature and Pressure Saturated. 
 
Most CPET protocols generally fall into two broad categories: incremental tests up to 
maximal exercise; constant work rate test. The former is based on the progressive increase 
of the exercise intensity in a short time duration and can be performed on a cycle or a 
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treadmill. They are often used to quantify the changes in exercise tolerance after an 
intervention. The latter is based on externally imposed and constant cycling or walking 
cadence that the patient must maintain until exhaustion.  
The primary endpoint of these protocols is thus the endurance time (or the distance which 
is a product of the speed and time). These tests are usually performed at a high fraction of 
peak exercise capacity typically representing 75–85% of peak cycling work rate or 80% of 
the estimated peak VO2 during the incremental shuttle walking test. An implication (and a 
disadvantage of this) is that the constant work rate protocols have to be performed with 
the knowledge of the peak cycling or walking capacity (60). These approaches provide 
different information and have different clinical indications.  
In the next chapters 3 and 4, we present our main contributions for this Thesis – the role 
of aerobic exercise determined by CPET on the ALS progression, and a feasibility study of a 
















3. The Exercise and the Disease Progression: 
 
This chapter presents the first main contribution of this thesis through an original article 
published in a peer review journal. 
 
3.1 The role of moderate aerobic exercise as determined by cardiopulmonary exercise 
testing (CPET) in ALS: 
 
 3.1 Introduction: 
 
Exercise is widely recommended to the general population due to its benefits to health and 
wellbeing. It improves the cardiovascular, respiratory, musculoskeletal, and endocrine 
functions and leads to psychological wellbeing. The role of exercise in the elderly, often 
with functional limitations and high risk of falls, is not yet completely clarified (61). In 
Amyotrophic Lateral Sclerosis (ALS), robust evidence about its risks and benefits is not 
established, and its putative neuroprotective role is still controversial (62,63).  
Disease-specific guidelines are general exercise recommendations, which are part of 
standard of care for ALS, with instructions for stretching, range of motion exercises, 
balance, and physical activity, are based on preclinical data, small clinical studies, and 
research on exercise in other neuromuscular diseases. Recent and increasing evidence in 
animal models and clinical studies reinforces the concept of potential benefit of an exercise 
program, suggesting that moderated endurance exercise can delay disease onset and 
increase survival (61-66). 
Aerobic exercise comprises a myriad of forms, and it is generally performed at a moderate 
level of intensity for longer duration than its counterpart: the anaerobic or strengthening 
exercise. The former refers to the use of oxygen to adequately meet energy demands 
during exercise via aerobic metabolism, which is critically related to the cardiorespiratory 
and vascular system’s capacity to supply oxygen to the muscles, and the ability to clear 
carbon dioxide from the blood via the lungs (64). When the intensity of the exercise 
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exceeds the rate of oxygen supply to the muscles by the cardiovascular and respiratory 
systems, lactate builds up and quickly makes it impossible to continue the exercise.  
The starting point of the exponential increase of lactate during a cardiopulmonary exercise 
testing (CPET) is the anaerobic threshold (AT). In ALS, AT may occur sooner than expected 
due to respiratory muscle weakness. However, no useful clinical symptom or sign is known 
as a marker of the AT and it can only be determined by direct measures of gas exchanges 
analysis through a cardiopulmonary exercise testing (CPET). On the other hand, the gap 
between AT and the respiratory compensation point (RCP), point of exercise intensity 
above which only anaerobiosis occurs, the training zone, may become narrowed or difficult 
to determine. In these circumstances, a safe limit is usually accepted by adding 10 to 20% 
of the work intensity at AT that must be uncovered. To overcome the difficulties and help 
the clinician to define the limits of the training zone and thus prescribe a moderate exercise 
program, the measurement of the aerobic capacity (VO2) at anaerobic threshold (VO2AT), at 
the Respiratory Compensation Point (RCP) or at peak of effort (VO2pk), can be done using 
CPET with gas exchange analysis. The training zone can also be set from the lowest nadir of 
the curve VE/VO2 to the lowest nadir of the curve VE/VCO2 (65). 
In addition, overtraining precautions are needed to avoid cramps, fasciculation, myalgia, 
prolonged post exercise fatigue, or soreness that are usually related to excessive neuronal 
hyperactivity and are clinical useful indicators of overwork. Post exercise fatigue should not 
interfere with daily life activities. If a patient has fatigue or pain that lasts longer than 30 
minutes after exercise, the program needs to be reduced and modified (66,67). Moreover, 
as the etiology of nerve cell death in ALS is complex and multifactorial, with excitotoxic 
mechanisms playing a role together with reduced oxidative metabolism (68), it is relevant 
to evaluate the effects of the exercise on the functional status in ALS patients. 
 
3.2 Objectives: 
This work aimed to assess the effects of a 6-months moderate aerobic exercise program 
with intensity determined by the limits found during the CPET, as compared to standard 
care. The primary outcome was the functional status of ALS patients. Additionally, we 




Study Design:  
We carried out a prospective, single blinded, quasi-randomized controlled trial (69), 
including 48 consecutive ALS patients referred to the Rehabilitation Department of Centro 
Hospitalar Lisboa Norte by neurologists who were blinded to the study. In our study, 
patients were allocated to two groups, based on geographical residence: Group 1 (G1, 𝑛 = 
24) included ALS patients with residence within the hospital outskirts; Group 2 (G2, 𝑛 = 24) 
included patients with residence outside the limits of the hospital area. All patients in both 
groups were ambulatory and able to perform CPET before the admission (T1), but only 6 
patients in G2 performed it mainly due to personal constraints. Table 15 describes the 
inclusion and exclusion criteria of the trial. 
Table 3. Inclusion/Exclusion criteria 
Inclusion Criteria 
 
Age between 18-90 years 
Diagnosis of definite, probable, or probable-laboratory supported ALS 
Disease duration from first symptoms between 6-24 months 
ALSFRS-R ≥ 30  
FVC (%predicted) ≥ 70% 
Exclusion criteria 
Other diseases, like cardiac insufficiency and lung disorders, and physical limitation to exercise 
training 
Heavy smoking habits, with laboratorial evidence of significant bronchial constriction 
Signs of associated dementia or psychiatric disorders 
Note: None of the patients were on tube feeding, invasive or non-invasive mechanical 
ventilation at admission (T1). 
 
Exercise Training Protocol: 
 Patients in G1 and G2 performed a standard care exercise program, as determined by the 
American Academy of Neurology guidelines (4). It included daily exercises, such as Range 
of Motion (ROM) exercises, limbs relaxation, trunk balance, and gait training. While 
patients in G2 performed the program at home or at other rehabilitation units, G1 patients 
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were supervised in our Unit and, in addition to the standard care, they also performed an 
aerobic exercise protocol two times per week on a treadmill, with training zone determined 
by CPET.  
The patient effort was set as of moderate intensity. When the training zone was not 
identified due to undetermined Respiratory Compensation Point (RCP), it was leveled-up 
20% of the work rate at aerobic threshold achieved in the CPET. Noninvasive ventilation 
(NIV) was added as needed for both groups and adjustments to the aerobic exercise 
program were made in accordance with cardiorespiratory responses of each patient in G1 
(23, 70-72). Body weight supporting system (BWSS) was used for patients with minimal 
lower limb weakness in G1. No BWSS was used during the training sessions in the G2. 
Assessments: 
 All patients were assessed at first visit (diagnostic visit, T0), at study entry (T1), and 6 
months after (T2) as follows. 
Revised ALS Functional Rating Scale (ALSFRS-R). 
All patients were evaluated with the revised ALS Functional Rating Scale (ALSFRS-R)each 
three months (38). This tool rates the functionality of the ALS patients in performing 
activities involving 4 different areas and sub scores, bulbar, upper limb, lower limb, and the 
respiratory function, each of its questions rated from 0 (total inability) to 4 points (no 
limitation). The last three questions address the respiratory function (dyspnea, orthopnea, 
and respiratory insufficiency) (38). 
Respiratory Function Tests (RFT) and Nocturnal Pulse Oximetry (NPO). 
 Forced Vital Capacity (FVC) and NPO were performed as described elsewhere (73,74). The 
percentage of the predicted value of FVC was recorded for posterior analyses. RFT including 
maximal inspiratory and expiratory pressures, phrenic nerve conduction studies and 
oxygen saturation provided by NPO in terms of mean percentage of oxygen saturation 
(%SpO2), the percentage of recording time with oxygen saturation lower than 90% (Sat < 
90%), and the number of oxygen desaturations per hour (ODI) were used to assess the need 




Cardiopulmonary Exercise Testing (CPET). 
Cardiopulmonary Exercise Testing (CPET) was performed at study entry (T1) and 6 months 
later (T2), using a treadmill (Woodway) coupled with a gas exchange analyzer (METALYZER 
3B) with ergo-spirometry system using a breath-by-breath technology developed by 
CORTEX systems (see figure 7). Data were extracted and analyzed with application software 
Metasoft Studio.  
The testing was customized and tailored to achieve symptom-limited exercise. A ramp 
modified protocol with increments of 5–15 Watts/minute, with a duration of 8 to 12 
minutes, including 3-4 minutes for warmup and cooling down. Patients were continuously 
monitoring with pulsed oximetry and three ECG leads (50). 
 
 
Figure 7. Patient performing CPET on the treadmill. 
 The peak effort and anaerobic threshold was attained in all included patients. We 
interrupted the test when the participants presented some of the following situations: 
reaching 75% of the predicted maximum heart rate (220-age), 55–65% of the predicted VO2 
maximum for age, gender, height and weight, and reaching fatigue evaluated by the Borg 
modified perceived scale or presented reduced neuromuscular performance. Other end-
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testing flags were complaints of lower limbs’ pain, dyspnea, presence of desaturation (SpO2 
≤ 88%), or the achievement of Respiratory Compensation Point (RCP) (75).  
The CPET variables analyzed were oxygen uptake expressed in L/min (VO2), in percentage 
of predicted, or in metabolic equivalents (METs) at peak effort, anaerobic threshold (AT), 
and the respiratory compensation point (RCP) when achieved, Dioxide Carbon output in 
L/min (VCO2), and minute ventilation in L/min (VE). 
 
Data Analysis and Statistics.  
Frequency distributions (median and interquartile) were calculated for age, disease 
duration, and categorical variables. Time measurements are expressed in months. The 
other continuous variables are presented with means ± standard deviation (m ± SD) and 
were expressed in absolutes values: time interval T0-T1, % FVC predicted, CPET variables 
(VO2 peak, VO2AT, MET’s, and VE), ALSFRS-R score, its sub scores (bulbar, spinal, and 
respiratory), and respective slopes.  
To assess the normality and variance, Kolmogorov Smirnov test was performed. Parametric 
tests were used to explore differences between groups and subgroups regarding total 
ALSFRS-R, its sub scores and slopes, % FVC, and CPET variables. Categorical variables 
(gender, region of onset, group, and use of NIV) were transformed from dummy to metric 
variables, to be submitted to stepwise multivariate linear regression analyses. We inputted 
the means for missing data points for both groups. Multiple regression model was applied 
to identify independent predictors of functional change at T2. All tests were 2-tailed, with 
significance set at 0.05 and power 0.7 (G∗. Power version 3.1.9.2). SPSS package software 
v. 22 was used. 
 
Ethical Committee. 
 The present study was approved by the joint Ethics committee Centro Hospitalar Lisboa 
Norte - Faculdade de Medicina de Lisboa, based on the national legislation (Reg. Number 




We included 48 patients, 32 men. Disease duration from onset was similar between G1 
(median = 9.50 months; IQR [25%–75%] 5.25–11.75) and G2 (median = 9.00 months; IQR 
[25%–75%] 5.25–12.00) (𝑝 = 0.7). The median age at study entry was 60.5 years for G1 (IQR 
[25%–75%] 54.25–76.25) and 63.0 years for G2 (IQR [25%–75%] 59.25–68.50) with 
nonsignificant difference (𝑝 = 0.4). Gender, region of onset, and ALSFRS-R and its sub scores 
were equivalent between groups. % FVC was significantly lower in G2 at entry (p=0.02). The 
study flow chart is shown in Figure 8. Clinical and demographic characteristics are 
summarized in Table 16. Twenty-four patients were randomized to G1, the active exercise 
group monitored in house and 24 to G2, the control group. 
At T0 (diagnosis), G2 had a non-significantly higher percentage of older women with 
bulbar onset – 30% versus 12% in G1; ALSFRS-R total score and its sub scores were also 
similar between groups. At the start of study (T1) there was no difference between sub 
scores (Bulbar score: p = 0.14; Spinal score: p = 0.12; Respiratory score: p = 0.93). All 
patients were stable with oxygen saturation (SpO2) ≥ 95%. 
At end of study (T2), ALSFRS-R was significantly higher in G1 (p = 0.035). There was a 
nonsignificant trend for a reduced sub scores slopes in G1. To determine whether there 
was a difference on the decline of ALSFRS- R between groups, we calculated the slope of 
ALSFRS-R total between T0 and T1 (𝑝 = 0.19; CI 95% [−0.69–0.14]) and between T1 and T2 
(𝑝 = 0.36; CI 95% [−0.86–0.32]), and the effect size (𝑑) = −0.26 showed a small but positive 







Figure 8. At the end of study, we can identify the main findings between groups. The arrows indicate the direction of the 
significant differences in G1 when compared with standard care group G2. The VO2 peak in G2 reduced 46% since T1. AECI 










Table 4. Clinical and demographic characteristics of the ALS patients at diagnosis (T0), 
admission to the study protocol (T1), and the end of study (T2). T-Test: mean and 
standard deviation values for both groups. 
 Group 1 (n = 24) Group 2 (n = 24) p value 
Male (%) 18 (75%) 14 (59%) 0.20 
Spinal onset form (%) 21 (88%) 17 (70%) 0.12 
Use of NIV T1-T2 (Yes – No) 14Y/10N 13Y/11N 0.75 
Age at onset (years) 63.21 (±13.0) 62 (±12.06) 0.42 
Time Interval (T0-T1) (months) 10.8 (±6.5) 10.79 (±7.7) 0.80 
% FVC (T1) 99.64 (±21.8) 80.0 (±21.0) 0.02 
ALSFRS-R total score (T0) 42.92 (±3.51) 41.13 (±4.83) 0.14 
ALSFRS-R total score (T1) 40.25 (±5.00) 37.25 (±4.9) 0.042∗ 
ALSFRS-R total score (T2) 34.1 (±7.1) 29.5 (±7.7) 0.035 
ALSFRS-R Tot sc. slope (T1-T2) 1.01 (±0.92) 1.28 (±1.10) 0.36 
ALSFRS-R bulbar slope (T1-T2) 0.15 (±0.24) 0.18 (±0.25) 0.62 
ALSFRS-R spinal slope (T1-T2) 0.66 (±0.64) 0.75 (±0.97) 0.68 
ALSFRS-R respiratory slope (T1-T2) 0.20 (±0.26) 0.30 (±0.32) 0.23 
G1: controlled exercise Group, G2: standard care group, T0: at diagnosis; T1: at start of to study; T2: end 
of study; Sp: spinal onset, Bb: bulbar onset; use of NIVT1T2: use of noninvasive ventilation during period 
of study; % FVC predicted T1: % forced vital capacity predicted at start of study (T1); ALSFRS-T Total Diagnosis: 
ALSFRS-R total at diagnosis moment; ALSFRS-RtotalT2: ALSFRS-R total at end of study; slope ALSFRS-R Total T1-
T2: slope ALSFRS-R total between start and end of exercise protocol (T1-T2); significant results (p ≤ 0.05) 
are represented in bold. ∗ALSFRS-R total score on T1 (Sub scores between G1 and G2 (NS): bulbar score: p = 0.14; 




Figure 9. Slope of ALSFRS-R total score between T0, T1, and T2 for both groups 
 
 Controlled exercise (G1) 
 Standard care (G2)  
 
Predictors of ALSFRS-R Total at End of Study: Multiple Linear Regressions Analyses. 
 We investigated the relationship between the functional score achieved at end of study 
and the following independent variables: age at study, gender, region of onset, use of NIV, 
group of intervention, and slopes of ALSFRS-R total. The stepwise multiple linear regression 
analysis adjusted to FVC at T1 showed that Bulbar Slope (B = −5.084; p = 0.12), Spinal Slope 
(B = −6.152; p < 0.001, and Group of intervention (B = 3.833; p = 0.021) were independent 
predictors. Together they explained 54.3% of the variance of the achieved ALSFRS-R score 
at end of study with adjusted R2 = 0.51. The regression model was significant (p < 0.001), 
and analyses with Durbin Watson test showed that the data had no autocorrelation. We 
found an effect size f2 = 1.04 favoring the intervention group.  
 
Influence of Use of Non-invasive Ventilation on the ALSFRS-R at T2. 
 
Subgroup 1A (n = 10) did exercise without NIV and Subgroup 1B (n = 14) used NIV during 
exercise sessions. G2 used NIV as needed. About 50% of patients in both groups used 
NIV (Table 16). However, a simple linear regression analysis did not confirm a significant 
























Controlled exercise  
Standard care 
Figure 10. Influence of Use of NIV on ALSFRS-R at end of study, Confidence Interval 95% (−3.08–
6.04; p= 0.7). 
 
Performance of Cardiopulmonary Exercise Testing (CPET) Variables during the Study. 
 In G1 all patients completed the exercise program, but only 19 (79%) were gait-
independent on at the second CPET evaluation. In G2, 6 patients performed a first CPET 
and only one patient of those did not perform the second CPET. Out of the remaining 
patients (18 patients), only six of them had had gait-independence at T2 (29%). 
 
CPET Variables at Peak Effort.  
 
We found no differences between groups regarding CPET variables (VO2, VCO2, VE, 
METs, and RCP) both at AT and peak effort at T1. The average peak VO2 in % of predicted 
for G1 was 60.8% (±21.2) and G2 was 44.16% (±12.45) (p = 0.07). As all the patients 
presented to CPET in T1 and T2 indicated equal variances on the homogeneity test, 
which allowed us to assume the implications to the differences between groups with 
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to VO2peak (𝑝 = 0.002), METs (𝑝 = 0.023), VCO2 (𝑝 = 0.011), and VE (𝑝 = 0.019) (see 
Table 5). The confidence intervals with significant differences at end of study for VO2 
peak are presented in Figure 11. 
 
T1: start of study, T2: end of study. VO2 predicted T1, VO2 predicted at start of study; % VO2 predicted T1, % 
VO2 predicted at start of study; VO2 peak (oxygen uptake at peak effort peak), VCO2 (carbon dioxide output), 
METS (metabolic equivalent), RCP (respiratory compensation point), VE (minute ventilation) expressed in 
L/min, and HR max (heart rate maximum) expressed in beats/minute. ∗Significant results (p ≤ 0.05) are 










(n = 24) 
Mean (±S. D) 
Group 2 
standard care 
(n = 6) 





VO2Predicted 2.06 (±0.58) 1.87 (±0.54) 0.47 
% VO2Predicted 60.8 (±21.2) 44.16 (±12.45) 0.07 
VO2peak T1 1.17 (±0.50) 0.83 (±0.32) 0.13 
VO2peak T2 1.05 (±0.36) 0.45 (±0.24) 0.002∗ 
METS T1 6.38 (±8.40) 3.74 (±1.10) 0.45 
METS T2 4.93 (±1.97) 2.64 (±1.28) 0.023∗ 
RCP T1 0.88 (±0.15) 0.83 (±0.08) 0.45 
RCP T2 0.86 (±0.13) 1.22 (±0.90) 0.42 
VCO2 T1 1.01 (±0.41) 0.69 (±0.27) 0.086 
VCO2 T2 0.95 (±0.40) 0.42 (±0.19) 0.011∗ 
VE T1 32.8 (±11.4) 24.06 (±7.3) 0.088 
VE T2 31.4 (±11.27) 17.8 (±5.21) 0.019∗ 
HRmax1 87.8 (±27.08) 95.2 (±17.1) 0.5 





Figure 11: VO2 Peak at T1 (𝑝 = 0.13, [CI: −0.78–0.11]) and at T2 (𝑝 = 0.002, [CI: −0.96–−0.25]). 
 
 
CPET Variables at Anaerobic Threshold.  
 
Regarding the work capacity in the anaerobic threshold, there were no significant differences at 
entry, but significant differences (p < 0.05) at T2 for VO2 and VCO2. These variables were significantly 
higher in G1 than in G2 (Table 6). The confidence interval with significant differences at end of study 
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(𝑛 = 24) 
(mean ± sd) 
Group 2 
(𝑛 = 6) 
(mean ± sd) 
𝑝 value 
𝑡-test (G1-G2) 
VO2AT T1 0.80 (0.25) 0.83 (±0.28) 0.8 
VO2AT T2 0.79 (±0.29) 0.40 (±0.15) 0.02∗ 
METS T1 3.62 (±1.7) 3.77 (±0.95) 0.8 
METS T2 3.54 (±1.38) 2.15 (±0.97) 0.07 
VCO2 T1 0.70 (±0.27) 0.71 (±0.29) 0.9 
VCO2 T2 0.68 (±0.35) 0.30 (±0.14) 0.03∗ 
VE T1 22.6 (±6.40) 23.3 (±8.17) 0.8 
VE T2 25.2 (±12.2) 14.62 (±2.85) 0.10 
T1: admission, T2: end of study. VO2 AT (oxygen uptake peak at anaerobic threshold), VCO2 (carbon 
dioxide output), METs (metabolic equivalent), and VE (minute ventilation) are expressed in L/min. 
∗Significant results (p ≤ 0.05) are represented in bold. 

















VO2 peak at anaerobic threshold 
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Aerobic Capacity and ALSFRS-R at End of Study.  
While patients in the G1 presented a stable condition regarding aerobic capacity, 
anaerobic threshold, and ventilatory capacity, the patients in the G2 showed significant 
decrease for the same aspects between 𝑇1 and 𝑇2 (Tables 5 and 6). Peak VO2 decreased 
10.25% in G1 and 46% in G2. There were significant differences on the oxygen uptake, 
CO2 output, and ventilatory capacity with a very high effect size (𝑑 = 1.99) analyzed by 
Cohen’s d on peak VO2 between groups. In addition, we found a significant and positive 
correlation between ALSFRS-R total score at end of study and peak VO2, METS, VCO2, 
and VE (see Table 7) but no correlation of ALSFRS-R at T1 with the same variables. 
 
Table 7. Correlations between ALSFRS-R total score and CPET variables on the peak of effort at 
T2. 
CPET variables (L/min) ALSFRS- R total score 
Pearson correlation (R) 
P-value  
Sig. (2-tailed) 
METS 0.491 0.017∗ 
RCP 0.256 0.239 
VCO2 0.580 0.004∗ 
VE 0.585 0.003∗ 
VO2Peak 0.544 0.007∗ 
ALSFRS-R (ALS functional scale revised), METs (metabolic equivalent), VCO2 (carbon dioxide output), RCP 
(respiratory compensation point), VO2 peak (oxygen uptake peak), and VE (minute ventilation) 




Nowadays, there is no strong evidence showing a potential harmful effect of exercise in 
ALS. The unpredictable progression of the disease, the different phenotypes, the frequent 
methodological shortcomings, and ethical issues affect most of the studies. 
A weak muscle can be damaged if overworked, which can easily happen in ALS as it is 
already functioning close to its maximal limits (76). This is the reason why some experts 
have discouraged exercise programs in ALS. These all make daily activities harder to do (77). 
Moderate exercise may have a beneficial effect on free-radical balance and improve muscle 
fiber oxidative metabolism, with potential impact against excitotoxicity (78). The role to 
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protect against oxidative stress has special significance as in ALS the motor neurons are 
particularly susceptible to oxidative damage (79). 
On top of this, if defective mitochondrial energy metabolism plays a role in cell death in 
neurodegenerative disorders and exercise may trigger added neuron excitability, we 
considered it of utmost relevancy to evaluate the effect of a moderate exercise program 
with work intensity close to the AT precisely determined by CPET. 
To the best of our knowledge, only three studies have been published on aerobic exercise 
capacity in ALS, with exercise intensity established by determination of CPET (80-82). All of 
them showed a reduced peripheral O2 utilization suggested to be consistent with physical 
deconditioning as the main cause of impaired exercise capacity in ALS, possibly related to 
impaired oxidative metabolism, early AT, and low peak oxygen uptake. The latter was not 
found in the other neuromuscular disorders. However, none of those studies evaluated the 
effect of a moderate exercise program on oxygen uptake around AT throughout disease 
progression.  
Our study is relevant due to the probable implications regarding the potential benefit of 
the rigorous exercise intensity prescription determined in the CPET and the risk of 
unsupervised exercise above the anaerobic threshold (83). Indeed, there are no clinical 
determinants of AT such as the time limit to fatigue, work intensity to fatigue, or ventilatory 
responses; in addition, peak oxygen uptake (peak VO2) cannot be used to estimate 
anaerobic capacity due to the large contribution of intraindividual variability (84) . 
This is the first exercise trial applying a moderate exercise protocol with intensity rates 
precisely defined through gas exchanges measures. Despite the limitations of a small 
sample, even over the apparent heterogeneity at the beginning of the protocol, but not at 
diagnosis, we counter these differences by recognizing that patients in G2 had a larger 
percentage of older women with bulbar onset who were expected to have a poorer 
prognosis regarding bulbar slopes and scores in G2. And patients in G1 had a larger 
proportion of spinal onset, who were expected to present a more progressive rate of 
decline of ALSFRS-R spinal scores or slopes. However, neither of these assumptions was 
observed, most likely because of the effect of exercise program that the two groups were 
instructed to follow during this period, showing no differences in the spinal, bulbar, or 
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respiratory slopes at T2 (Table 4). Using a multiple linear regression model, we found the 
group of intervention as a significant independent predictor (B = 3.833; 𝑝 = 0.021). 
These observations taken together with the significant difference in ALSFRS-R spinal sub 
score favoring G1 patients at T2 (𝑓2) = 1.04 and the mean difference of functional decline 
expressed on the ALSFRS-Total score between groups after 6 months, also showing a small 
but positive effect favoring the exercise group (𝑑) = 0.26 (Figure 9), strengthen our 
interpretation of a positive effect of exercise in this study. 
Our results concur with the recent study by Lunetta and colleagues (85) that also showed 
that a strictly monitored moderate exercise program may significantly reduce motor 
deterioration in ALS patients. Interestingly they were not able to improve survival, an 
essential point to demonstrate a neuroprotection effect, and the authors were not clear 
regarding the definition of moderate exercise. 
Actually, the possibility of a muscle fiber to increase its size and becoming stronger while 
maintaining endurance capacity depends primarily on a set of different factors, such as the 
application of appropriate stimuli (i.e., sustained contractile activity combined with short, 
powerful mechanical loading), availability of the essential substrates, the capacity to 
increase oxygen transport (e.g., by improving heart and lung function or angiogenesis, 
hematocrit and myoglobin), and prevention of tissue hypoxia with chronically reduced 
cellular energy status. 
Moreover, the cellular oxygen supply can be improved by increasing the capillarization, the 
hematocrit, or myoglobin concentration (86), in which the regulation involves the hypoxia 
inducible factor-1 (HIF-1𝛼). The HIF-1𝛼 mediates the expression of erythropoietin and 
angiogenic growth factors, such as vascular endothelial growth factor (VEGF), known to be 
implicated in ALS pathogenesis (87). VEGF can be increased in serum concentrations in ALS 
patients both by moderate exercise and noninvasive ventilation as previously shown by our 
team (88,89). Thus, we took it into consideration and applied a moderate exercise program 
and NIV as needed in order to enhance a hypothetical neuroprotective effect, such as 
suggested by Dal Bello-Haas and Florence, 2013 (7). 
Unexpectedly, NIV did not exert any influence on ALSFRS-R at T2 (𝑝 = 0.46, 𝑅2 = 0.02) (Figure 
10). Given the well-known effects of NIV on survival, quality of life, exercise tolerance, and 
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sleep quality, the most likely explanation is related not only to the very similar approach of 
initiation of NIV in both groups but also to the short timeframe of observation. 
No doubt these factors will also have to be considered in further studies, when addressing 
the major issue of neuroprotection and survival benefit. However, whether these results 
corresponded just to an expected initial distal plasticity as shown by Blizzard and 
colleagues, 2015 (90), or a positive effect on neuroprotection, as suggested in a previous 
study of our team (89), remains to be explained and will be the focus of a future longitudinal 
study that due to the extensive and expensive nature of the needed evaluations will justify 
a multicenter trial.  
Regarding the performance of CPET variables during the study, the anaerobic threshold 
(AT), also called the ventilatory threshold (VT), is an index used to estimate exercise 
capacity. It constitutes a reliable and reproducible index of submaximal exercise intensity 
that is defined as the highest VO2 that can be sustained without developing a lactic acidosis, 
a response that is generally observed at 40 to 60% of peak VO2 independently of patient-
motivation. 
A key utility of AT is that it provides information at a submaximal level of exercise intensity 
(i.e., it does not require a physiologically maximal exercise effort) and is also considered 
more consistent with a patient’s ability to perform daily activities, especially because 
exercising beyond the AT for sustained periods eventually results in fatigue. 
In addition, we used the most common method that entails the graphing values of VCO2 
versus VO2 to identify the AT as the point where there is a shift in slope along a line of 
identity between these gas measurements (modified V-slope method) (65). Mean values 
of oxygen uptake at AT expressed in % of achieved peak VO2 at T1 was 69%, which allowed 
us to cast some doubts over the deconditioning clinical situation of our patients in both 
groups at entry in the study. At T2, patients in G2 showed significant differences with a very 
rapid decrease of VO2(AT), though it happened in an even higher percentage (88%) of VO2 
peak probably due to a primarily neurogenic impairment. On the other hand, these results 
also show that deconditioning was not the main reason of poor performance, usually 
identified with low VO2 and early AT, though it still is a common point of view. 
75 
 
Together with a respiratory compensation point (RCP) > 0.80 (see Table 5) in both 
evaluations and groups, it shows not only the existence of peripheral muscle 
underutilization of oxygen as described by other authors, but specifically a primarily 
impairment of muscle performance probably due to atrophy and loss of muscle bulk with 
a late increase in lactate and low VO2, exactly the opposite results for a mitochondrial 
myopathy with an early increase in lactate, combined with a very low VO2 peak, as shown 
by Takken and colleagues, 2010 (91). Likewise, we recognized a primarily neurogenic 
impairment instead of deconditioning. 
Our study does not address the important issue of muscle oxygen extraction impairment, 
a dysfunction recently described in ALS (92). In future studies this evaluation should be 
added to investigate the impact of exercise in ALS. 
Peak VO2 is an important metric because it defines the limits of the cardiopulmonary 
system. Although commonly expressed in L/min, this value naturally increases as body 
mass increases. To better facilitate inter-subject comparisons, peak VO2 is usually 
normalized and expressed in ml/Kg/min. However, the relationship of peak VO2 and weight 
is not linear with inherent imprecision associated with weight normalized values; thus, we 
recorded VO2 either in L/min or in percentage of predicted values or in METs. 
Remarkably, our results showed a significant more stable course of peak VO2 in patients of 
G1 suggesting that exercise prescribed and performed according to the CPET evaluation 
has a positive impact on functional decline. However, we cannot discard the effect of a 
supervised exercise program with expert physiotherapists also able to modify the work 
intensity according to individual physiologic responses at each session.  
Moreover, it is not possible to exclude a bias effect due to a better respiratory function in 
G1 (%FVC), though its measurement is sometimes problematic in patients with bulbar 
weakness (88). Indeed, the lower FVC in G2 patients was likely due to an insufficient tight 
seal with pursed lips for accurate measurement. Nevertheless, we adjusted our results to 
the FVC by a stepwise multiple linear regression analysis and found an effect size 𝑓2 = 1.04 
favoring the intervention group strengthening our principal conclusion. These findings 
support our hypothesis that aerobic exercise with control of intensity leveled by CPET can 
be safe and beneficial for ALS patients prolonging ambulatory skills. 
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Indeed, exercise, when prescribed and supervised appropriately, may be physically and 
psychologically important for people with ALS, especially in the earlier stages of the disease 
and before significant muscular atrophy occurs. Although it may not improve the strength 
of muscles already weakened by ALS, strengthening exercises with low to moderate 
weights and aerobic exercises such as swimming, walking, and bicycling, at submaximal 
levels may be important components of an overall management plan (7). An exercise 
prescription in a rehabilitation program for ALS patients should follow an assessment by 
CPET with aerobic capacity measurements and be performed under strict and competent 
supervision. 
3.6 Conclusions: 
Moderate exercise protocol with CPET evaluations can be safe and beneficial and should 
be considered in the multidisciplinary approach to ALS patients. 
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Tele-monitoring of a home-based 
exercise program in ALS:  
A feasibility study   
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Amyotrophic Lateral Sclerosis (ALS) is associated with progressive functional limitation and 
impairment in accessing interdisciplinary care centers (93), causing dropouts in hospital-
based rehabilitation programs. In addition, potential exercise benefit in ALS, still is a 
controversial issue. Recent evidence favors exercise in early stages (85) and highlights the 
need of further research, namely on aerobic exercise (7). Currently, exercise 
recommendation is mainly supported by exploratory clinical studies in ALS and results 
observed in other neuromuscular diseases as described in the previous chapter. 
4.2 Objective: 
 
We have been concerned on using cardiopulmonary exercise test (CPET) to quantify 
exercise intensity, to avoid overtraining in patients undergoing rehabilitation.  
Considering the common problem of limited access to interdisciplinary care in ALS, we have 
conducted a feasibility study using a Tele-Monitoring System (TMS) to record physical 
effort, compliance and adverse events from patients performing home-based exercise 




We prospectively included 10 patients willing to participate (written informed consent) 
followed in our unit. We selected a homogenous ALS population respecting the following 
inclusion criteria:  disease duration between 6-24 months; ALS revised-functional rating 
scale (ALSFRS-R) ≥30 and forced vital capacity (FVC) >70% of the predicted value. Smokers, 
as well as patients with significant bronchial constriction on spirometry, with other medical 
conditions or clinical signs of dementia, were excluded.  
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All patients were taking Riluzole©, but none was using tube-feeding or non-invasive 
ventilation (NIV) at entry. Patients underwent a symptom-limited treadmill-ramp protocol, 
with the training zone detected between the first and second ventilators thresholds (VT1 
and VT2) by CPET using a gas exchanges analyzer (CORTEX 3B®). Peak oxygen uptake and 
carbon dioxide output were analyzed and metabolic equivalents (METs) were derived. 
Patients were committed to perform at least one exercise session/week using the Tele-
monitoring system and advised to exercising above the VT1, not surpass 75% of the 
predicted maximum heart rate (HR) [220-age]) and to keep percutaneous oxygen 
saturation (SpO2) ≥ 93%.  
Each session consisted of walking on a treadmill or walk outdoor (approximately 15 minutes 
with 5 minutes for warming up phase before and 5 minutes later for cooling up phase) for 
6 months. Compliance was assessed by the number of exercise sessions completed by the 
patient as recorded in the Tele-monitoring system and a minimum of 24 session was 
defined as supporting protocol feasibility. 
 
4.3.1 Remote Mobile Monitoring System 
This digital platform allows regularly monitor the readings of a selected set of vital signals 
through non-intrusive wireless bio-sensors biosensor with a secure Bluetooth connection 
to a mobile phone, including Heart Rate and SpO2 (finger oximeter). See figure 13. The vital 
signals can be defined by the healthcare team and requested for the monitoring provider 
previously. The data can be available within seconds after the readings. This allow us to 
verify the exercise performance remotely in a real time, and if the patient’s effort is suitable 
or not (Figure 14). This approach allows the healthcare team make changes in theirs 







Figure 13. Functioning of Remote mobile monitoring system – Vital Mobile Cycle, with permission 




Data were available for analyses within seconds after the recordings. Subjects (patients and 
caregivers) received instructions about how to use the devices. Investigators were available 
on phone or email to solve any question. 
 The following adverse events were systemically evaluated: fatigue, dyspnoea, SpO2 ≤88%, 
Hear rate and pain that could impair exercise. Differences between ALSFRS-R and METs at 






Figure 14. Graphic representation of the Telemonitoring System measures in the digital platform. 
 
 4.3.2 Ethical Committee: 
The study was approved by the Ethics Committee of Hospital Santa Maria-CHLN, and 
patients signed an informed consent. 
4.4 Results: 
Clinical features and cardiorespiratory response to exercise are summarized in table8.  No 
patient dropout and no significant adverse event impairing exercise was disclosed. In 6 
patients, the maximum HR was transitorily above the maximum predicted value, which was 
promptly correct by the monitoring protocol. Regarding compliance, the average number 
of sessions was 29. In the end of this study, 70% of patients presented a level of physical 
activity (adjusted to gender and age) of  4.6±0.85 METs, which is considered a moderate 
level (95). In the six months period, both ALSFRS-R and METs declined significantly (p=0.008 
and p=0.015, respectively) as expected; however, both FVC and SpO2 on exercise did not 











The use of tele-rehabilitation in the healthcare delivery model has been successfully trialled 
in patients with various diseases. When patients are unable to access the specialized 
centres, tele-monitoring can allow the healthcare team to interact with patients and their 
families in the home environment. Moreover, it has the potential to engage local and 
community-based services with the specialized centres in the decision-making process. The 
benefits of tele-health for ALS patients on NIV have been reported before (96).  
In this study, patient and caregivers considered the tele-monitoring system user-friendly 
and the compliance was excellent. The continuous monitoring O2 saturation and Heart Rate 
during exercise demonstrated that a home-based exercise program is clinically safe when 
designed around the anaerobic threshold (VT1) thus limiting overtraining with possible 
Table 8. Results (10 ALS patients), mean (± S.D) * 
Male/female ratio 7/3 
Age at Study 57 (±9.1) 
Region of Onset (Spinal/Bulbar) 9/1 
Disease Duration (Diagnosis – T1) months 7.6 (±4.12) 
ALSFRS-R total slopeT1-T2 mean (± S.D) - 0.81 [ 0 – (-) 2.16] 
 At entry  At 6 
months 
p-value  
%FVC  101.8 (±20.3) 95.4 (±13.4) 0.066 
ALSFRS-R total score 43.0 (±2.1) 36.4 (±6.9) 0.008 
METS mean   5.6 (±1.7) 3.8 (±1.4) 0.015 
SpO2 mean 95.25 (±1.2) 94.73 (±1.7) 0.944 
Sp – Spinal; Bb – Bulbar; PMHR – Predicted Heart Rate Maximum, %FVC – Forced Vital Capacity predicted, 
ALSFRS-R – Amyotrophic Lateral Sclerosis Functional Rating – Revised, METs– metabolic equivalent mean 
reached on CPET, HR– Heart Rate mean; SpO2 mean - Percentage of Saturation of oxygen. Significant 
differences are in bold (Wilcoxon signed-rank test). *S. D - Standard deviation 
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fatigue or dyspnoea. Patients with overtraining signals were timely contacted and advised 
to keep their physical effort as predefined, which would be impossible without this facility.  
Although, we are positive about the advantages of tele-monitoring exercise in ALS, a few 
constraints should be mentioned before larger implementation, such as underestimation 
of the perceived fatigue, data-protection, data accessibility, financial investment and the 
large physician time consuming. Nonetheless, we believe that further technological 
advances will certainly incorporate algorithms and alerts to advising patients or caregivers 
whenever the performing exercise are out of the limits pre-established by the clinical team. 
 4.6 Conclusions: 
 Despite of the small sample of patients and the exploratory profile of this study, we suggest 
that tele-monitoring use for exercise control is feasible and safe in ALS patients. Future 
studies should include cost-benefit evaluation and impact on the quality of life of patient 
and caregivers. 









Based on the paper published: 
Braga AC, Pinto A, Pinto S, de Carvalho M. Tele-monitoring of a home-based exercise program in 













Management of Respiratory Failure with 





5.1 Respiratory Insufficiency in ALS – a brief review: 
 
The respiratory muscle dysfunction present in ALS has a strong impact on survival and 
quality of life of these patients. The consequent respiratory failure, usually associated to 
pneumonia and ineffective cough, is the most frequent cause of death. Attempts to 
compensate the respiratory failure is an important piece of ALS management. Besides the 
respiratory muscles, we must pay attention to neural control of breathing (97). Although 
still disputable, ALS is probably associated with alterations on the central respiratory 
network including possible changes of rhythm generation with impact on respiratory 
muscles (28). The so-called respiratory muscles are those that provide the motive power 
for the act of breathing. Thus, although many of these muscles are involved in a variety of 
activities, such as speech production, cough, vomiting and trunk motion, their primary task 
is to displace the chest wall rhythmically to pump gas in and out of the lungs (98). 
The muscles responsible for the proper functioning of our breathing are divided into four 
functional groups: inspiratory muscles, expiratory muscles, accessory muscles of the breath 
and the muscles of the upper airways. 
The inspiratory muscles are the external intercostal and the diaphragm. The serratus 
posterior and anterior may help inspiration. The expiratory muscles are the internal 
intercostal and abdominal muscles. The accessory muscles are the sternocleidomastoid, 
scalenus anterior, medius and posterior, pectoralis major and minor and latissimus dorsi. 
Some of these muscles are illustrated in the figures 15, 16 and 17. 
 
 






Figure 16. Diaphragm muscle, (Anatomy & Physiology – Visible Body® app 2015) 
 
 
Figure 17. Expiratory muscles, (Anatomy & Physiology – Visible Body® app 2015) 
 
The muscles of the upper airways involved in the breathing process are the genioglossus 
muscle (tongue), the hyoid muscles and the Laryngeal muscles (not present in the figures).  
The laryngeal muscles are divided in: intrinsic and extrinsic laryngeal muscles. The intrinsic 
muscles group is compounded by: adductor muscles (lateral cricoarytenoid muscle, 
thyroarytenoid muscle and the interarytenoid muscle; the abductor muscle, posterior 
cricoarytenoid muscle; and the tensor muscle, cricothyroid muscle. The extrinsic muscles 
group is formed by the infrahyoid strap muscles (sternothyroid, sternohyoid, and 
thyrohyoid muscles), the mylohyoid, digastric, geniohyoid, and the stylopharyngeus 
muscles, all acting in concert to provide laryngeal stabilization, and indirectly affecting the 
vocal fold position (99). 
The laryngeal muscles must control the vocal folds for multiple functions, opening for 
inspiration, closing for airway protection during swallow, and rapid opening and closing to 
build up pressure for airway clearance during cough (100). Respiration and swallowing have 
opposing biomechanical effects on upper airway musculature; dilation for inspiration to 
allow unobstructed air intake into the lungs, which contrasts with oropharyngeal 
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compression for squeezing the bolus through the pharynx and the upper esophageal 
sphincter. The control of these two systems is coordinated in neurons involved in these two 
integrative systems in the brain stem (101). 
In many neuromuscular disorders, muscle weakness involves the respiratory muscles to an 
equal or even greater extent than other skeletal muscles. The degree of limb muscle 
weakness cannot be used as a reliable guide to the presence of respiratory muscle 
impairment, since the correlation between the two may be quite poor (98,102,103). 
Respiratory muscle involvement may also be masked because patients with weak limb 
muscles spontaneously decrease their overall activity level, thereby reducing the daily 
physiologic effort made by the respiratory system. In addition, early symptoms of 
diaphragmatic muscle weakness may be subtle (104). For all these reasons, it is not unusual 
for respiratory muscle weakness to go undetected until a clear respiratory failure be 
precipitated by an acute episode of pulmonary aspiration or infection.  
The supine position, sometimes adopted during sleep, comes up a mechanical 
disadvantage to a weakened diaphragm. Afterwards, the first signs of respiratory 
discomfort affecting the quality of sleep arise. With the ongoing progression of the disease, 
problems like hypoventilation develops. The main symptoms of hypoventilation include 
non-restorative sleep, fatigue, daytime drowsiness and morning headaches (73). 
Paralysis of the diaphragm is the most often cause attributed to the origin of respiratory 
disorders during sleep. This muscle represents 60% to 70% of inspiratory muscle strength 
and has been the subject of numerous studies, which show its involvement in the 
respiratory insufficiency in ALS. Diaphragm failure leads to symptoms of dyspnea, and 
dyspnea at rest is a symptom meaning severe paresis of the diaphragm (105). 
Patient must undergo regular respiratory function assessment to identify early signs of 
impairment. The importance of early detection of respiratory insufficiency is also related 
to the use of NIV that prolong survival and improve patients' quality of life (106). 
The current clinical guidelines (23,73) and last Cochrane systematic review (6) refers that 
NIV is the treatment of choice in the management of Respiratory Insufficiency  in ALS. 
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In our unit at Centro Hospitalar Lisboa Norte, the respiratory function assessment is 
performed each three months, except for slow progressions. It includes percentage of the 
predicted value of Functional Vital Capacity (FVC) and Slow Vital Capacity (VC), and Sniff 
Nasal Inspiratory Pressure (SNIP) - in particular for patients with poor cooperation when 
performing spirometry; maximal inspiratory (MIP) and expiratory (MEP) pressures, 
inspiratory pressure in the first 100 milliseconds time frame during MIP effort (P0.1), 
phrenic nerve motor response and overnight oxygen saturation provided by Nocturnal 
Pulse Oximetry (NPO). 
 NPO calculates the mean percentage of oxygen saturation (% SpO2), the percentage of 
recording time with oxygen saturation lower than 90% (Sat <90) and the number of oxygen 
desaturations per hour. All these complementary investigations are used to define the 
proper time for NIV adaptation, in addition to clinical assessment (73).  
FVC is predictive of hypercapnia (107) and it is generally used to monitor respiratory 
function in ALS patients (108-111). Measurement of FVC (or slow vital capacity) in the 
supine position may be a better indicator of diaphragm weakness. In normal individuals, 
there is a small decrease in FVC (or slow vital capacity) in the supine position compared to 
FVC (or slow vital capacity) in the sitting position. The decrease in FVC in the supine position 
(or slow vital capacity) is greater in patients with diaphragmatic weakness. The more recent 
study published by Pinto (109) describe that FVC and slow vital capacity are very highly 
correlated, and both are strongly correlated with MIP and MEP, still they are moderately 
correlated with respiratory sub-score of ALSFRS-R in spinal-onset patients, but correlation 
with respiratory sub-score of ALSFRS-R in bulbar-onset patients is poor. As the diaphragm 
is the only active inspiratory muscle during the phase REM sleep (Rapid Eyes-Movement 
sleep), patients with diaphragm weakness likely experience nocturnal hypoventilation, 
oxygen desaturation and sleep-disordered breathing. On polysomnography ALS patients 
shown reduced total sleep time, with frequent arousals, central hypopnea, increased sleep 
in the phase 1 and decreased REM sleep duration (112). Home NPO is a simple and helpful 
procedure that is valid as a criterion for initiating and monitoring NIV effectiveness. 
Generally, it is used as an instrument for modifying NIV settings. The guidelines of the 
American Academy of Neurology (AAA) and European Federation of Neurology Societies 
recommend the initiation of NIV when symptoms of respiratory impairment are associated 
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with abnormal findings on measuring respiratory function. The table below shows the 
current criteria (73)  used to assess the need of NIV.  
Table 9. Signs and symptoms, and Respiratory function tests related to respiratory 
muscle weakness in ALS: 




Disturbed sleep due to nocturnal desaturation/arousals 
Morning headache 
Use of auxiliary respiratory muscles at rest 
Paradoxical respiration 
Daytime fatigue 
Excessive daytime sleepiness (ESS > 9) 
Respiratory Function tests: 
Forced vital capacity <80% of predicted value 
Sniff nasal pressure <40 cmH2O 
MIP <60 cmH2O 
Significant nocturnal desaturation on overnight oximetry 
Morning blood gas pCO2 > 45 mmHg 
Table ESS, Epworth Sleepiness Score; NIPPV, non-invasive positive pressure ventilation (73) 
 
In addition to NPO, currently, there are studies that support the use of Non-Invasive 
transcutaneous measure of CO2 (TcCO2) to directly assess nocturnal hypercapnia and to 
detect residual hypoventilation with higher sensitivity (113). Additional monitoring of CO2 
can help to differentiate between hypoxemia related to ventilation/perfusion mismatch 
and hypoventilation, and also is useful in determining the degree of compliance to NIV. 
(114,115).  
Nowadays, the existing management options are focused on the control of symptoms and 
aims to alleviate the effects of disease progression on respiratory function, they are: NIV, 
assisted-coughing device, respiratory physiotherapy to help in the clearance of secretions 
and prophylactic vaccination.  
The next two sub-chapters presents outcomes from works related to the management of 
respiratory insufficiency in ALS. 
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Sub-Chapter 5.2 - A look at the diversity on management of respiratory failure in 
Amyotrophic Lateral Sclerosis;  
Sub-Chapter 5.3 - Can NIV parameters settings and changes overtime predict functional 




5.2 A look at the diversity on management of respiratory failure in Amyotrophic 
Lateral Sclerosis: 
 
This work presents a discussion about the still present lack of consensus on the 
management of respiratory failure in ALS patients. It is based on an editorial published in 
Respiratory Care. 2015 April; 60(4):625-6. 
In 2015, Sancho et al (116) performed prospective study about medically stable ALS 
patients, to determine possible clinical or functional predictors of need of Non-Invasive 
Ventilation (NIV) during an acute episode of lower respiratory tract infection.  
The authors used the criteria of the American College of Chest Physicians (117) to initiate 
NIV at home. Currently, the decision to initiate NIV presents some variability, as previously 
acknowledged in the literature (118). If we analyze Sancho’s study regarding the current 
NIV guidelines, most of those patients should have started NIV, as they presented a 
percentage of predicted Functional Vital capacity (%FVC) < 75% and Maximum Inspiratory 
Pressure (MIP) lower than - 60 cm H2O. In addition to those criteria, currently most ALS 
centers consider also the presence of respiratory signals/symptoms. 
Sancho et al (2015) reported a population of 33 patients, 23 subjects with spinal-onset and 
10 bulbar-onset. From the whole sample, 18 patients did not require NIV during an acute 
event of respiratory infection. In this group (n=18), 15 patients had spinal-onset and 3 
bulbar-onset. In a multivariate logistic regression analysis, the only variables that predicted 
the need for NIV (n=15) were %FVC (Odds Ratio 1.06, CI 95% 1.01-1.11) and Peak Flow 
Cough (Odds Ratio 2.57, 95% Confident Interval 1.18-5.59).  However, most of them were 
spinal patients, who present a better prognosis compared to bulbar patients. Certainly, the 
region of onset should be considered when analyzing predictors for NIV.  As ALS population 
was small, further research is necessary to validate those findings. 
 Another interesting aspect in this study was the use of mechanically assisted coughing, 
which was recommended when Peak Cough Flow was lower than 4.25 L/s. But it was not 
specified how many spinal and bulbar patients used cough-assist device. 
Andersen and colleagues (119)  performed a study on the effects of the cough-assist device. 
The authors stressed the importance of laryngeal dysfunction, which can compromise the 
benefit of cough-assist in bulbar patients, particularly in those with hypotonic bulbar 
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paresis. Laryngeal adduction severely reduces the size of the laryngeal inlet, with negative 
implication in airflow and cough-assist. In these cases, we must consider whether invasive 
mechanical ventilation should be a better option to manage respiratory support and 
airways clearance. 
The guidelines advising about the decision to initiate NIV have been updated. The main 
criteria, beyond of %FVC, include: sniff nasal inspiratory pressure (SNIP), maximal 
inspiratory pressure (MIP), symptoms related with respiratory muscle weakness, nocturnal 
and diurnal desaturation and hypercapnia, and – more recently – phrenic nerve response. 
But cultural and economic aspects still influence on the NIV usage (23,72,73,120). 
It should be remembered that, following initiation of respiratory support at home, 
caregivers have a very important role in the ventilatory support. This is particularly true for 
patients with bulbar ALS who decide to receive invasive-mechanical ventilation after failure 
of NIV. Besides the use of a ventilator, there are other respiratory support aids that 
caregivers need be able to use. Vianello and colleagues (121) suggest that administration 
of the cough-assist is effective and safe even if provided by trained non-professional 
caregivers and should be part of disease management at home. It could be used in 
combination with NIV to decrease the need for hospitalization and increase patient quality 
of life. 
 However, the revised report of European Task force on ALS clinical management (73) refers 
that mechanical ventilation causes strain on caregivers, reducing their quality of life by 
increasing their responsibilities related to the management of the ventilator, and increasing 
the caring costs. Thus, we must be careful regarding the evaluation of the emotional, 
physical, social and psychological capacity of caregiver to deal with increasing needs of care 
of a family member with ALS.  
The caregiver quality of life and their support should be considered as a independent 
variable with relevant weight when evaluating possible predictors of success or failure of 
NIV in patients with ALS.  
In Europe, some countries are using tele-monitoring system to follow-up patients with ALS 
using NIV. The association of home-monitoring with more efficient portable ventilators 
might implicate higher costs to the Health Service, but recent studies have demonstrated 
cost-effectiveness by the use of the NIV home-monitoring in European countries (96,122). 
Pinto and colleagues referred that the investment for implementing this system is not 
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significant, in particular considering long-term cost estimation, since it would reduce 
unnecessary hospital visits (96).  
Health care models that combine technology with patient-centered care may imply directly 
on non-medical costs, such as days of wages lost due to absenteeism of caregivers. Future 
studies must include the impact of tele-monitoring on costs of the health services, including 
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5.3 – Can Non-Invasive Ventilation settings predict functional and survival 
outcome in ALS patients? 
 
This study analyzed the predictors of functional decline (ALSFRS-R) and survival related to 
NIV settings, NIV compliance data, Nocturnal Pulse Oximetry (NPO) and Pulmonary 
Function Tests (PFT). It has received an award as the best original research abstract 
(Respironics Fellowship in Mechanical Ventilation) in the 58th American Association of 
Respiratory Care (New Orleans, 2012) and published in the Journal of Community Medicine 
and Health Education (7:521, 2017). 
5.3.1 Introduction: 
The lack of low-cost specific tools, which could be associated with ALSFRS-R to define 
prognosis, is a constraint factor in the follow-up of ventilated patients. Abundant evidence 
shows the NIV critical role in prolonging life in compliant patients (4,70). Compliancy to NIV 
is frequently defined by the number of hours of use during the day (nhu/d) and is generally 
accepted as a predictor of survival (123). However, proper management implies not only 
the need to obtain full adherence, but also synchrony and comfort to achieve NIV 
effectiveness (124). As such, other variables beyond number of hours/day, namely the 
ventilation settings of NIV equipment need to be evaluated regarding their potential role 
as markers of functional and survival outcome. As the causes of death in ALS are diverse 
(125-129), it is important to clarify whether respiratory discomfort on NIV is present from 
NIV start to near the time of death, and if they could be amenable by intervention.  
5.3.2 Objectives: 
This study aimed to investigate the prognostic factors of functional decline and survival in 
ALS ventilated patients, among compliant ventilated ALS patients, considering all variables 
recorded by the equipment software (96), from the initial adaptation until death or end of 
study.  We hypothesized that different clinical decisions regarding parameters settings will 
affect both survival and compliancy and that our results would contribute and reinforce the 
need of close surveillance of ALS ventilated patients as shown by Claude Rabec and 





Our study followed an exploratory, observational and prospective design. We included 60 
ALS ventilated stable subjects followed in our ALS clinic from 2007-2012, with regular use 
of NIV (> 4h/day), Compliancy was evaluated and considered effective as described 
elsewhere, more than 4h of use per day (nhu/d) after one month of NIV initiation 
associated with improvements on NPO - SpO2mean > 93%, resting heart rate between 60-
90 bpm and eupnea with lower breath rate on NIV (BR< 16 bpm). 
Included patients were classified with definitive, probable or probable-laboratory 
supported disease, on the revised El Escorial criteria, aged between 18 to 75 years. Subjects 
with gastrostomy, cognitive impairment or other medical condition, as heart or lung 
disorders, oncological diseases or previous history of stroke were excluded. Patients were 
prospectively evaluated at entry, over disease progression and in the end of 5 years-period. 
Patients were split in two groups: G1 (n=29) - subjects who died over the follow-up-period 
of 5 years; and G2 (n=31) - subjects who were alive in the end of the study time (2007-
2012). All data were registered and compared between groups, including: timing to NIV 
adaptation expressed as a percentage of time of the total disease duration; NIV device 
settings; compliancy data; functional decline (ALSFRS-R); duration of NIV use (days); and 
total survival from disease onset. 
Functional Assessment and NIV initiation: 
 All patients were clinically evaluated every 3 months, functional evaluation was quantified 
by ALSFRS-R (38). Indication for NIV initiation was supported by the presence of  respiratory 
symptoms (respiratory sub-score of the ALSFRS-R < 12) or signs of respiratory insufficiency, 
associated with  abnormal NPO findings (SpO2mean < 95% for patients without previous 
respiratory condition) (73,74) , or reduced FVC (< 80%), or decreased MIP (< 60 cmH20), or 
hypercapnia, in accordance to the NICE in 2010 (23).  
NPO was measured continuously during sleep, by fingertip infra-red pulse oximeter 
(Wristox2®, Model 3150-Nonin). Mean oxygen saturation (SpO2mean), percentage of time 
with O2 saturation below 90% (Sat< 90) and the number of dips/hour associated with ≥ 4% 
lowering of SpO2 were measured. A minimum of 6 hours of recording was necessary for 
analysis. PFTs were performed using standard equipment according to the American 
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Thoracic Society (ATS) recommendations (130). Predicted values of conventional 
pulmonary function parameters were calculated by normalizing to the reference values 
proposed by the European Community for Steel and Coal (131). We used predicted FVC 
value and predicted MIP and MEP values. All these investigations are part of our usual 
routine care. Evaluations were performed with a periodicity of 3 months. Functional scores 
and PFTs were evaluated by physicians blinded to the study.  
Upon recommendation, all patients were ventilated with a Bipap Goodknight 425-ST bi-
level device (Tyco™ Healthcare Group LP, California, USA), in our unit. Initial, after achieving 
full compliance (≥4 hours of use/ day), and last parameters settings, were registered as well 
as compliancy data on the same occasions (132) . 
Our Ethical Committee approved this study and participants signed informed consent. 
Data and Statistical Analysis:  
Kolmogorov-Smirnov test analyzed the normality of the sample. We compared the 
differences between the two groups using a chi-square test, t-test or a Mann-Whitney non-
parametric test as appropriate. Survival curve from symptoms onset was plotted using 
Kaplan-Meier estimates. Correlation analyses among variables were tested. Categorical 
variables (gender, onset-region, and group) were transformed from dummy variables to 
metric variables to be integrated into the Cox-regression models. 
In addition, continuous variables with non-uniform distribution were dichotomized and 
tested with chi-square test and if significant differences were found, they were 
dichotomized and binned by its median value for further consideration in a subgroup 
analysis.   We used multiple Cox regression models to identify predictors of functional 
decay and survival. The independent variables were:  
NIV settings – Inspiratory Positive Airways Pressure (IPAP), Expiratory Positive Airways 
Pressure (EPAP), Inspiratory sensitivity (IS), Expiratory Sensitivity (ES), Rise time (rT), Breath 
Rate back-up (BR back-up);  
NIV compliancy data – the percentage of Spontaneous Cycles (%SC), the mean Breath Rate 




NPO measurements - Heart Rate (HR), Mean oxygen saturation (SpO2mean), percentage of 
time which SpO2 recording was below 90% (Sat< 90); 
RFTs – Forced Vital Capacity (FVC), Maximum Inspiratory Pressure (MIP), Maximum 
Expiratory Pressure (MEP), Inspiratory pressure 100 milliseconds into an occluded 
inspiratory effort (P.01), Partial pressure of CO2 (PaCO2) and Partial pressure of O2 (PaO2).  
The sample size was calculated with G*Power, Version 3.1.9. (Effect size d = 0.8). The 
statistical significance level was p≤ 0.05.  
5.3.4 Results: 
Group Comparisons: 
Sixty subjects were included in this study (43 males and 17 females divided in two groups: 
G1 (n=29; dead); and G2 (n=31; alive) at 5-years of follow up.  Men were predominant in 
both groups. NIV was initiated at 50% time of the total disease duration in both groups 
(p=0.12). At admission, no significant differences were found between groups regarding 




Table 10.: Demographic and clinical characteristics of groups at NIV adaptation* 
 G1 (N=29) G2(N=31) p-value 
Male/female ratio 24/5 19/12 0.39 
Age of Onset 63.4(±13.2) 67.2(±10.7) 0.23 
Type of Onset(S/B) ratio 22/7 23/8 0.29 
Limbs (Upper/Lower) ratio 15/14 16/15 0.62 
Disease Duration up to NIV (days)  764.5(±599.6) 564.7(±316.0) 0.12 
ALSFRS-R (mean ±S. D) 
ALSFRS-R Total 31.86(±6,09) 33.52(±3.69) 0.20 
Spinal sub-score 18.74(±5.7) 20.16(±3.56) 0.16 
Bulbar sub-score 10.45(±2.01) 10.84(±1.84) 0.43 
Respiratory sub-score 10.72(±1.75) 10.71(±1.73) 0.97 
Respiratory Function Test (mean ±S. D) 
Forced vital Capacity (FVC), %predicted 82.7(±19.58) 92.7(±19.8) 0.74 
Maximum Inspiratory Pressure 55.3 (±24.0) 53.15(±23.4) 0.53 
Maximum Expiratory Pressure 68.8(±26.2) 72.8(±19.93) 0.42 
Mouth Occlusion Pressure 91.9(±31.3) 89.0(±32.8) 0.74 
Nocturnal Pulse Oximetry (mean ±S. D) 
SpO2mean 93.64(±2.7) 93.75(±1.24) 0.10 
Sat<90 5.86(±15.03) 3.15(±3.53) 0.60 
Heart rate 73.34(±14.08) 68.10(±11.05) 0.12 
*Non-significant difference between groups at admission. G1 – dead; G2 – 




In the end of the 5-years’ time, significant differences were found between groups 
regarding the functional score and NPO data: heart rate and Sat < 90 are summarized in 
table 11. 
 G2 showed a higher functional score on the ALSFRS-R [p=0.001], as well as on the spinal 
and bulbar sub-scores (p=0.006 and p=0.01, respectively). 
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The respiratory sub-score (p=0.76) and functional slopes (ALSFRS-R total [p= 0.21], spinal 
[p=0.35] and respiratory [p=0.40] slopes) showed no significant difference. The bulbar 
slope revealed significant differences, with a slower decline in G2 (p=0.025). Sat < 90 
(p=0.034) and mean heart rate (p= 0.005) in NPO were more favorable in G2 at the end of 
the observation period.  
 In general, NIV setting were similar between groups, but breath rate back-up was lower in 
G2 (11.98±1.40; p<0.028). Regarding compliancy data, BR mean showed a lower value in 





Finally, Kolmogorov-Smirnov test analyzed the distribution of continuous variables. As the 
variable IPAP at the end of observation showed a non-uniform distribution between 
groups, it was dichotomized and binned by its median value (IPAP=18 cmH2O). As we 
identified significant differences (p=0.05) between groups related to level of IPAP (See table 
12), we also considered this IPAP level as new dependent variable (IPAP < or > 18cmH2O) 
and performed a subgroup analysis to evaluate its effect on functional decline and survival. 
 Table 11.  Clinical characteristics at end of study (t-test) 
 Mean ± S. D G1 G2 P value 
 Functional Scores and Slope 
 Bulbar sub-score 6.04 (±4.44) 9.00 (±4.13) 0.016* 
 Spinal sub-score  7.13 (±5.86) 13.92 (±8.15) 0. 006* 
 Respiratory sub-score 7.12 (±2.81) 7.32 (±1.86) 0.76 
 ALSFRS-R Total 18.08 (±8.67) 28.51 (±11.49) 0.001* 
 Bulbar slope/month 0.24 (±0.28) 0.08 (±0.9) 0.025* 
 Spinal slope/month 0.70 (±0.93) 0.48 (±0.75) 0.350 
 Respiratory slope/month 0.17 (±0.17) 0.22 (±0.23) 0.401 
 ALSFRS-R Total slope/month 1.10 (±1.39) 0.72 (±0.61) 0.213 
 Nocturnal Pulse Oximetry 
 SpO2mean 92.51 (±3.29) 93.90 (±1.61) 0.064 
 Sat < 90 10.30 (±20.75) 1.20 (±1.96) 0.039* 
 Heart Rate 77.53 (±16.39) 66.39 (±9.21) 0.005* 
 Bipap Ventilation Settings 
 Breath Rate Back up 12.76 (±1.39) 11.92 (±1.40) 0.028* 
 IPAP 18.46 (±2.59) 17.76 (±3.42) 0.40 
 EPAP 4.7 (±0.48) 4.4 (±0.68) 0.07 
 IS 1.3 (±0.8) 1.3 ±0.8) 0.73 
 ES 2.0 (±1.7) 1.7(±1.4) 0.76 
 Compliancy Data  
 BR mean 13.97 (±1.66) 12.88 (±1.42) 0.011* 
 %Spontaneous Cycles 30.0 (±23.2) 28.6 (±20.1) 0.9 
 I: E ratio 0.4 (±0.08) 0.05 (±0.05) 0.7 
 Rise Time 1.4 (±0.7) 1.3 (±0.7) 0.5 
 Clinical Characteristics 
Time to NIV (days) 764.5 (±600.6) 564.7 (±316.8) 0.12 
 Disease Duration from Onset(days) 1482.7 (±895.1) 1340.3 (±518.6) 0.46 
 Total Use NIV (days) 769.9 (±554.9) 698.3 (±501.0) 0.60 
 *Statistical significance p≤ 0.05 in bold.  G1 – dead; G2 – alive. Legends – see Data and 
Statistical analysis section 
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353.00 430.50 449.00 279.50 356.00 413.00 308.00  
Wilcoxon W 788.00 836.50 884.00 714.50 762.00 878.00 773.00  
Z -1.83 -0.07 -0.01 -1.97 -0.92 -0.39 -1.56  
Asymp. Sig 
(2-tailed) 
0.07 0.94 0.99 0.05 0.36 0.70 0.12  
Legend: * Group 1 - IPAP <18 cmH2O; Group 2 - IPAP >18 cmH2O 
 
Correlations Analyses: 
 Statistical significant correlations (Pearson two-tail sig.) were searched between the 
dependent variables Disease Duration from symptoms onset and Total Use of NIV (days) 
with Functional scores and slopes, ventilation settings, NIV compliancy, NPO and PFT as 
independent variables. We found significant correlations among the following variables 





Table 13. Partial correlation analyses among Functional Slope per month, NIV 
settings, PFT, NPO, Disease duration and Total use of NIV 
Variables  Disease Duration Total Use of NIV 
Functional Slope per month 
ALSFRS-R total slope R -0.408 - 0.362 
p 0.006* 0.016* 
Bulbar slope R -0.296 -0.269 
p 0.051 0.07 
Spinal Slope R -0.386 -0.341 
p 0.010* 0.024* 
Respiratory Slope R -0.375 -0.432 








































R – Pearson Correlation, p – p-value. *Correlation is significant at the 0.05 level (2 tailed); ** 




Multiple Cox Regression Analyses. 
We carried out a Multiple Cox regression analyses stratified to type of disease onset to 
identify predictors for ALSFRS-R Total slope from onset to death or end of study, for Disease 







Table 14.  Predictors of ALSFRS-R Slope among NIV settings, NPO, PFT, and clinical 
characteristics. Multiple Cox regression model  
Variables B SE Wald p-value 
NIV settings/Compliacy 
% Spontaneous Cycles 0.457 0.165 7.633 0.006 
I : E ratio 21.360 9.383 5.182 0.02 
NºHoursUse/day 0.319 0.222 2.073 0.15 
BR mean -2.177 1.357 2.572 0.10 
IPAP -1.153 0.604 3.649 0.05 
EPAP -1.147 1.532 0.560 0.45 
IS -4.624 1.475 9.826 0.002 
ES 1.369 0.582 5.536 0.01 
rT 8.580 3.949 4.720 0.03 
BRbackup 2.819 1.669 2.852 0.09 
Nocturnal Pulse Oximetry (NPO) 
SpO2mean 1.313 0.873 2.264 0.13 
Sat<90 -0.046 0.167 0.078 0.78 
HR 0.047 0.079 0.352 0.55 
Pulmonary Function Test (PFT) 
% FVC -0.120 0.089 1.829 0.17 
MIP -0.195 0.117 2.795 0.09 
MEP 0.331 0.163 4.116 0.04 
P01 -0.189 0.075 6.377 0.01 
PaO2 0.075 0.103 0.536 0.46 
PaCO2 -0.239 0.208 1.328 0.24 
SatO2 3178 1.391 5.222 0.02 
Clinical Charactheristics 
Gender -15.901 7.000 5.160 0.02 
Evolution until NIV -0.015 0.005 8.042 0.005 
Age at onset -0.116 0.133 0.762 0.38 
Disease duration 0.012 0.004 9.011 0.003 
Legends –  NIV settings/Compliancy –  percentage of Spontaneous Cycles (%SC),   Inspiration: Expiration 
ratio (I: E), Number of hours usage/day (nhus/day),  mean Breath Rate observed (BR mean), Inspiratory 
Positive Airways Pressure (IPAP), Expiratory Positive Airways Pressure (EPAP), Inspiratory sensitivity (IS), 
Expiratory Sensitivity (ES), Rise time (rT), Breath Rate back-up (BR back-up);  NPO measurements -  Mean 
oxygen saturation (SpO2mean), percentage of time which SpO2 recording was below 90% (Sat< 90), Heart 
Rate (HR); PFTs – Forced Vital Capacity percentage of the predicted value (% FVC), Maximum Inspiratory 
Pressure (MIP), Maximun Expiratory Pressure (MEP), Inspiratory pressure 100 milliseconds into an 
occluded inspiratory effort (P.01),  Partial pressure of O2 (PaO2), Partial pressure of CO2 (PaCO2) and 
Oxygen Saturation (SatO2). -2 Log Likelihood: 57.507; X 2: 60.921; p<0. 001.*Statistical significance p≤ 
0.05 in bold. 
104 
 
 The variables with relevant explanatory power on ALSFRS-R Total slope among the NIV 
parameters data were (table 14): percentage of spontaneous cycles (%SC) (B=0.45; p= 
0.006)  inspiratory/expiratory ratio[I:E] (B= 21.3; p=0.02), rise time (RT) (B=8.58; p= 0.03), 
inspiratory sensitivity (IS) (B= - 4.62; p= 0.002), expiratory sensitivity (ES) (B=1.36; p= 0.01) 
and IPAP (B= -1.15; p= 0.05),  with a significant model :  -2-Log LL = 57.5; Chi-sq = 60.92; p< 
0.0001; and effect size f2: 0.56. 
Regarding the predictors for the disease duration from onset, we identified in a significant 
Cox regression model (-2-Log LL = 61.381; Chi-sq = 36.22; p< 0.0001) similar variables 
related to NIV settings and compliancy, which were found as predictors for the functional 
slope per month (table 15). However, a Cox regression model did not identify any 






Survival estimates with Kaplan-Meier curves in the G2:  
Survival function with Kaplan-Meier curves were analyzed with and without censoring as 
all patients in G2 were alive, and no significant differences were found regarding the 
disease duration from onset as well as to total NIV use (days). 
Table 15.  Predictors of Disease Duration among NIV settings and compliancy. 
Multiple Cox regression model  
Variables B SE Wald p-value 
NIV settings  
% Spontaneous Cycles 0.091 0.044 4.335 0.037 
I:E ratio -2.136 4.643 0.212 0.645 
IPAP -0.343 0.162 4.470 0.034 
EPAP -1.361 0.765 3.162 0.075 
IS 1.689 0.719 5.515 0.019 
ES -0.473 0.205 5.320 0.021 
RT -1.058 1.014 1.089 0.297 
BRbackup 0.780 0.594 1.724 0.189 
NIV Compliacy 
NºHoursUse/day 0.173 0.089 3.798 0.051 
BR mean -1.814 0.784 5.357 0.021 
Legend - see Data and Statistical Analysis section. *Statistical significance p≤ 0.05 in bold 
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As all patients in G2 were alive at the end of the study we only considered the Kaplan-
Meyer estimates curve regarding functional decline. In addition, we evaluated the KM 
estimates for disease duration from onset and Total NIV use facing the new group identified 
by the average of IPAP (GIPAP 1: IPAP <18cmH20; GIPAP 2: > 18 cmH20) used by all participants. 
We performed a Kaplan-Meier statistic stratifying groups by IPAP level, we observed that 
the total time of NIV use was significantly longer in patients using higher levels of IPAP in 
the end of the observation period (L-R: Chi–sq = 6.251; p= 0.012) - see figure 18. In addition, 
the slope of the respiratory sub-score also showed to be significantly influenced by IPAP 
level, with faster slopes in the group with lower IPAP level (L-R: 124.03, Chi-sq:25.98, 
p<0.001, see Fig. 19) 
 
 


















Figure 19. Kaplan Meyer curve estimate for rate of respiratory sub-score slope per month 
stratified by the IPAP level. Legend: 1 IPAP: <=18.0 cmH20; 2 IPAP: > 18.1+ cmH20 
 
5.3.5 Discussion: 
Non-Invasive Ventilation (NIV) allows a wide range of ventilation parameters and settings, 
thus it is mandatory to have accurate information about these issues to better understand 
the interplay between patient and ventilator (120).  Currently, the usual criteria to follow-
up ALS ventilated patients has only considered compliant those patients under NIV that 
have used the equipment more than 4 hours/ day.  In the present study we also considered 
whether it was effective.  
We endeavor to follow-up home NIV only in stable ALS patients to obviate the need of a 
closer surveillance and, at the same time, to accommodate the frequently different degrees 
of compliancy in each patient. However, to validate compliance, symptoms of discomfort 
related to masks use (leaks, face/nose pain, nasal congestion, etc) that could influence 
adherence (133) were solved by high quality technicians who visited patients regularly to 
solve those issues (134).  










Survival Function at mean of covariates 
Level of IPAP 
1 IPAP <=18.0 





Despite some limitations detailed later, this study showed for the first time the importance 
of analyzing the compliancy data and ventilation settings as independent predictors of 
functional decline evaluated by its slope/month (see table 14), the NIV use in days (Fig.18) 
and of the total disease duration from symptoms onset (Fig. 19).  
Our results strongly suggest that the variables affecting the respiratory comfort of patient 
(IPAP, IS, rT, and BR back-up), are indeed a prerequisite to a better NIV compliance (% of 
spontaneous cycling, I/E ratio, nº of hours of use/day and the BR mean) and can influence 
the functional decline.  
Moreover, the higher the IPAP pressure and the higher inspiratory sensitivity, the lower 
total ALSFRS-R decline/month, the lower ALSFRS-R respiratory sub-score decline/month as 
well as the longer NIV use (L-R: χ2=6.251; p=0.012), all of these results, together with higher 
ALSFRS-R slope associated to higher rT and higher BR back-up are in line with Dreher and 
colleagues work in 2010 (135). This latter work and the Kim and colleagues contribution 
(2011) (136) also recognized the value of high intensity non-invasive ventilation in stable 
hypercapnic COPD patients in a randomized crossover trial.  
Overall, these results showed that the functional decline was significantly affected by 
parameter settings. Indeed, the faster slopes were related to higher percentage of 
spontaneous cycling, lower inspiratory and expiratory ratio; lower inspiratory sensitivity 
and lower IPAP, thus suggesting the need of a close surveillance and above all, the need to 
keep patients’ respiratory mechanics and central drive well captured by the ventilator 
during sleep. 
The limited available literature about the Patient-Ventilator Asynchrony in neuromuscular 
patients suggests that severe asynchrony may be associated with increased work of 
breathing and sleep disruption (137,138). Patient-ventilator interaction is complex and 
multifactorial, and it is dependent on respiratory system conditions, various disease states, 
neural function and clinical response.  When optimized, the patient-ventilator interaction 
can provide to patient more comfort during positive-pressure breaths, and improvements 
on the sleep quality results in a better quality of life (139-142).  
108 
 
Although influenced by a number of factors, the mechanical augmentation of tidal volume 
during higher IPAP pressure decreases the intensity and duration of inspiratory muscle 
contraction, reducing patient work of breath (143) . The percentage of spontaneous cycles 
activated by patient also influenced the functional decline showing that the higher % of 
spontaneous cycling was associated with higher ALSFRS-R slope/month (B= 0.457; p= 
0.006)and a lower disease duration (B=0,091, p=0,037). This is probably explained by the 
increase of unnecessary inspiratory effort. 
 A study carried out by Vitacca and colleagues (144) reported discrepancies between Bilevel 
mechanical ventilator settings to optimize work of breath and settings chosen by COPD 
patients to maximize comfort.  
In general, longer inspiratory time improve oxygenation by increasing the mean airway 
pressure (longer period of high pressure increases mean airway pressure over the entire 
respiratory cycle), allowing gas re-distribution from more to less compliant alveoli. It can 
also decrease the peak pressure by decreasing inspiratory flow.  
Regarding the role of the Rise time as functional slope predictor, it is well known that it 
determines the speed of rise of the flow or pressure. A very short rise times may be more 
uncomfortable for the patient and longer rise times may result in a lower tidal volume   or 
higher pressure being required due to decrease of inspiratory flow. 
The inspiratory sensitivity determines how easy it is for the patient to trigger the ventilator 
to deliver a breath. In general, increased sensitivity is preferable to improve patient-
ventilator synchrony, but excessively high sensitivity may result in false or auto-triggering. 
In this study, the IS also showed a beneficial effect in the ALSFRS-R decline (B= -4.624; 
p=0.002) and this result is just in line with a study performed by Gonzales (145) that 
described the adjustment of cycling criteria and rise time that could potentially impact 
breathing frequency, work of breathing, trigger timing and patient-ventilator synchrony, 
with potential consequences for the respiratory comfort and compliance of patient. 
ALS patients with respiratory symptoms have hypoxic events, hence a full adherence to NIV 
with higher IPAP and inspiratory sensitivity and low breath rates can help to minimize this 
problem, modulating the neural drive as shown by the statistically significant difference of 




As ALS natural history is closely related to hypoxia, and motor neurons are particularly 
vulnerable to hypoxic conditions because of their high oxygen consumption and poor 
antioxidant enzymatic defenses (87), the ventilation settings and its changes help to 
provide improvements on respiratory symptoms as well as on daytime arterial blood gas 
levels and nocturnal oximetry measurements. Thus, it is important to carefully titrate 
parameters settings until full compliance is achieved and have a close follow-up up to the 
final disease stages.  
Currently, the use of capnography measurements showed to be an efficient tool both for 
assessing nocturnal hypoventilation and compliance to NIV treatment of ALS patients (136) 
and should be more available. Although important, in this present study we did not 
evaluated this method.   
The main findings in this study were related to predictor role of NIV settings and nocturnal 
pulse oximetry data. Indeed, minor changes on the nocturnal pulse oximetry data (Sat< 90; 
Heart Rate and SpO2 mean), became significantly different close to end of clinical evolution 
or end of study, and they were related to disease duration from the onset. This suggests 
that a status of eupnea, which provides a heart rate and breath rate closer to resting 
pattern during the night, must be achieved as soon and longer as possible. In addition, 
oximetry studies during follow-up can help to identify and the correct changes on abnormal 
pattern of sleep.  
We recognize the limitations impacted by the type of study and emphasized that these 
results may have been influenced by sample size and ALS center biased. Therefore, more 
studies should be conducted on a fully randomized trial to validate these findings.  
In the future, the need for an individualized approach based on closer clinical management 
should be part of treatment attitude for ALS ventilated patients. Problems that can affect 
compliance deserve closer attention and should be addressed timely throughout the 
disease process as at the end of the disease small but significant parameters settings 
change do impact on functional decline.   
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Compliance plays a very important role in clinical decision-making. It can make the 
difference on the survival in these patients and suggests that NIV can have a modifier role 
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The Support for the Caregivers  




















6. Home Caregivers Training Program for Amyotrophic Lateral Sclerosis: 
Insights from a Pilot Project: 
 
This work reports a feasibility study on a training program for ALS caregivers considering 
the learning level achieved at the end of Training program. This training program was 
developed together with Portuguese ALS association and funded by National Rehabilitation 





ALS generates a total dependency for all activities of daily life, and the subsequent 
respiratory muscles weakness leads to the need of respiratory support. The health care 
management of patients with ALS focuses on the symptomatic control (146) to maximize 
the quality of life and decrease the burden of the disease for patients and caregivers (147). 
 Previous studies have reported that patients under ALS specialized and multidisciplinary 
care have greater benefits (147) . Currently, the specialized and multidisciplinary health 
care management is part of the American Academy of Neurology–endorsed ALS quality 
measures (24). 
ALS is a disease with long-term health care needs, and ideally, community health services 
linked to specialized clinical services must perform its clinical management. ALS 
progression exposes caregivers to a high level of physical and psychological demand.  The 
constant physical effort of caring patients with mobility impairment and the management 
of interventions such as mechanical ventilation and use of feeding devices at home can 
contribute for a high level of distress (146) . The lack of specialized centers, or the distance 
between patient home and the health centers that could provide support for patients with 
ALS during clinical intercurrences, may potentially contribute to the rate of readmissions of 
ALS patients in acute hospital services. Providing specific and basic training for ALS 





We evaluated the level of learning achieved at the end of Training Program and whether 
this type of intervention should be recommended for efficacy testing. This study did not 
test the effectiveness. The Training Program was based on the most recent ALS clinical 
management guidelines and aimed to provide skills which could allow the ALS patients’ 
caregivers caring of their family member at home safely. 
6.3 Methods: 
We carried out an exploratory and observational feasibility study with ALS patients 
‘caregivers, after the completion of the Training Program for ALS caregivers created by the 
Portuguese ALS association. ALS patients were followed up in the ALS/Motor Neuron 
Disease clinic of two academic hospitals: in Lisbon and Oporto city. The criteria to 
participate in the Training Program were: be a family member or formal caregiver or known 
person of an ALS patient, literacy, age above 18 years, and availability to be present during 
the period of the TP. The exclusion criteria were: be a caregiver of other neuromuscular 
clinical conditions than ALS (e.g., Duchenne dystrophy, Guillain-Barre syndrome, etc.), 
illiteracy and lack of availability to full time presence during the Training Program. 
Caregivers were informed about the Training Program during the Neurology consultations. 
 In addition, informative material, such as flyers and posters, were displayed on in the 
Neurology and Rehabilitation services in both hospitals, and in the website of the ALS 
Portuguese association. The participants did not receive any financial compensation. The 
participation was free of costs but limited to 15 participants for each Training Program, to 
better accommodate the participants for hands-on sessions and providing enough time for 
discussion. Trainers contacted the participants via telephone to identify reasons for 
absences after the Training Program has started. 
 
Feasibility Criteria 
The compliance was assessed through a diary register of the list of participants. All 
participants had to be present at least 75% of the Training Program to receive a certificate 
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of completion. Each Training Program should have at least 10 participants to be considered 
feasible. 
Learning Assessment 
Participants undertaken a written examination with multiple-choice questions. The 
number of questions allocated to each module was weighted based on complexity and 
relevance of each module (see Table 16). The trainers considered the mark ≥50% as a 
successful completion on the written exam due to the extensive and massive amount of 
information that had been provided to nonprofessional caregivers. The trainers considered 
that 50% of learning retention after the whole Training Program would be a reasonable 
start point for future editions. 
The Training Program 
It was developed by the team of health care professional volunteers of the Portuguese ALS 
Association which included a registered nurse, a physiotherapist and a social worker, all of 
them with clinical and academic expertise in neuromuscular disease. A biomedical engineer 
helped the ALS Association team with the augmentative and alternative communication 
module. The main goal of the Training Program (TP) was to help patients and caregivers to 
cope with the main challenges usually reported during the consultations in the local 
ALS/MND clinic over the years. 
The total duration for each Training Program were 2 full days + 1 half day in the weekends 
(32 hours total duration). It was divided into 10 modules with theoretical and hands-on 
practice approaches which included the following topics: 
• Module 1: General concepts about ALS: a brief and didactic clinical review about 
the disease; 
• Module 2: Rights and duties: A social worker presented to the caregivers the current 
legislation and social support provided by the National Health Service and the Social 
Security Department; 
• Module 3: Communication skills: A registered nurse demonstrated strategies to 
reach a better communication between ALS patients, caregivers and health care team; 
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• Module 4: Basic daily care and nutrition: A registered nurse demonstrated practical 
guidance to performing activities of daily life, such as hygiene care and feeding - since oral 
intake to the management of percutaneous endoscopic gastrostomy (PEG); 
• Module 5: Therapeutic management: Because ALS is a nonexclusive disease, a 
registered nurse provided orientation to the caregivers about polypharmacy and 
comorbidities; 
• Module 6: Augmentative and Alternative communication devices: A biomedical 
engineer demonstrated how the technology could help patients and families to maintain a 
communication pathway; 
• Module 7: Mobility, transfer, and positioning: A physiotherapist demonstrated 
basic techniques to help the caregivers to maintain the patient’s mobility, how to transfer 
patients from the bed to chair/wheelchair as well as provided strategies for a better 
positioning of the patient in a safe way. It was also demonstrated how to avoid pressure 
wounds in ALS patients and back injuries for the caregivers; 
• Module 8: Respiratory support: A physiotherapist explained the main reasons for 
using a respiratory support in ALS patients and what kind of devices might be used; 
• Module 9: Emergency situations: A registered nurse discussed about the most usual 
clinical situations and how to manage them, such as choking, falls, and some of 
consequences of the immobility which need special attention of the caregivers, such as 
deep venous thrombosis; 
• Module 10: Caregiver self-care: A physiotherapist and a registered nurse discussed 
with the caregivers about the impact of burnout on their mental and physical health and 








1.  General concept about ALS 3 
2.  Rights and obligations for patients and caregivers 2 
3.  How to communicate better with ALS family members and health care team 1 
4.  Basic daily care and nutrition 2 
5.  Respiratory support: noninvasive ventilation, oximetry assessment, and use of 
Cough Assist® 
2 
6.  Polypharmacy, comorbidities, and follow-up 1 
7.  Augmentative and Alternative communication 3 
8.  Mobility, transfer, and positioning (pressure wound prevention and use of 
technical aid for mobility and transfers) 
3 
9.  Emergency situations x 
10.  Caregiver self-care 5 
Note. ALS = amyotrophic lateral sclerosis; X= none question was allotted to this module 
 
The theoreticals approaches included slide presentations and round tables that discussed 
the main concerns of the caregivers related to the theme in each module. The practical 
sessions were performed using hands-on approaches, and the caregivers had the 
opportunity to handle the most used equipment and devices in ALS patients such as: 
wheelchairs, transfer board, splints, portable ventilators (BIPAPs), oximeter, Cough Assist® 
machine, nebulizers, PEG and technical aids for feeding and for helping patients to change 
clothes. 
The characteristics of the Training Program regarding the resources used and the time 
allotted in each module are described in Table 17. 
Funding and Project Management 
The project “Training Program for ALS Caregivers” was submitted on behalf of Portuguese 
ALS association for funding through the national program of the National Institute for 
Rehabilitation. It has been approved and funded 2 years consecutively.  
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Financial support under this national program aims to promote the exercise of the rights of 
people with disabilities through the development of annual projects for nongovernmental 
organizations (NGOs) that integrate the principles of United Nations Convention on the 
Rights of Persons With Disabilities (148).  
The funding allowed performing 5 Training Programs during 2 years in two big cities of 
Portugal: Lisbon (Southern region—3 TP) and Oporto (Northern region—2 TP). It helped on 
the acquisition of technical aids used during the hands-on sessions, stationery items and 
travel expenses of the trainers’ team as well as acquisition and dislocations of equipment 
from Lisbon to Oporto city (a distance around 450 km between both). The Training Program 
in Lisbon was held in the installations of Portuguese ALS association and, in Oporto, in the 
São João do Porto Academic Hospital. 
At the end of each Training Program, participants received a questionnaire to score the 
level of satisfaction with their participation using a Likert scale rating from 1 to 5 (1 = very 
unsatisfied, 2 = unsatisfied, 3 = slight satisfied, 4 = satisfied, and 5 = very satisfied). This 
questionnaire reported details about the structure of the program (level of knowledge of 
the instructor, methodology used [theoretical/hands-on], relevance of contents, 
audiovisual equipment, objectivity and duration of the Training Program). It was a 
compulsory request from the funder. The Training Program project was approved by the 
Ethical Committee of the National Institute of Rehabilitation, Govern of Portugal. The study 
was approved by the Institutional Review Board of the ALS Portuguese Association. 
 
 Statistical Analyses 
We used descriptive statistical analyses—frequency distribution for categorical variables 








Table 17. Description of the Training Program. 












1.  General concepts about 
ALS 
Brief clinical review about 
ALS 
PT 2 — T 
2.  Rights and obligations 
for patients and 
caregivers 
Social support and 
legislation of the 
National Health System 
for ALS patients 
SW 2 — T 
2nd day 
3.  How to communicate 
better with ALS patients 
and health care team 
Communication skills Nurse 4 — T 
4.  Basic daily care and 
nutrition 
Hygiene care, feeding 
(oral intake and PEG) 






5.  Respiratory support Respiratory management: 
noninvasive ventilation, 
oximetry assessment, 
and use of Cough 
Assist®. 







6.  Polypharmacy, 
comorbidities, and 
follow-up 
Therapeutic management Nurse 2 — T 










8.  Mobility, transfer, and 
positioning (pressure 
scar prevention and use 
of technical aids for 
mobility and transfers) 






9.  Emergency situations: 
choking, deep venous 
thrombosis, sudden 
death falls—What to 
do? 
Emergency situations Nurse 1 — T 
5th day 
10. Caregiver self-care Burnout prevention PT/nurse 4 — T 
Written examination and 
satisfaction questionnaire 
completion, and closure of 
the Training Program 
Assessment  2 — T 
Total   32 hours 
Note. ALS = amyotrophic lateral sclerosis; PEG = percutaneous endoscopic gastrostomy.  aAids to daily living—dressing, 







A study flowchart (Figure 20) summarizes the sociodemographic characteristics, final marks 
in the written exam, scores in the questionnaire of satisfaction and the relationship 
between the caregiver and the ALS patients. The participation on the Training Program was 
excellent. The total number of registrations requested for all the Training Programs was 84. 
However, the number of participants was lower than the inscriptions requested.  
We had 77 participants for all five Training Programs. Each one had an average of 15 
participants. The main reason to declining participation was the lack of secondary caregiver 
during the weekends. The percentage of successful completion in the written exam 
(average) was 70% (73. 32% in Lisbon, and 78. 47% in Porto). Table 18 presents the 
percentage of the participants with correct answers for each module. The level of 
satisfaction with the participation in the Training Program was 80.5% very satisfied, 13% 
satisfied and 6.5% for abstentions. 
Thirty percent of participants were not present full time during the Training Program and 
the main causes were absence of a secondary caregiver and/or a clinical intercurrence with 
the ALS patients. All participants reported that the participation in the Training Program 
was a very pleasant experience with great interaction and sharing of knowledge that helped 























Figure 20. Study flow chart 
Assessed for eligibility 
(n= 77 participants) 
Excluded (n=7) 
 Declined to participate 
due absence/ 
unavailability of 2nd 
caregiver 
 
Written exam – 73. 32%: 
 
Lisbon (n=46) 
 35 females, age (m± 
S.D): 47 ± 15.4 yrs. 
 17 formal caregivers  
 29 Informal caregivers 
Written exam – 78. 47% 
Oporto (n=31) 
 29 females, age (m± 
S.D): 39 ± 9.0 yrs. 
 15 Formal caregivers 




84 registrations received  





Table 18. Percentage of the participants with correct answers for each module (N = 77). 
Modules  
1.  General concept about ALS 84% 
2.  Rights and obligations for patients and 
caregivers 
95.4% 
3.  How to communicate better with ALS 
family member and with health care team 
81.8% 
4.  Basic daily care and nutrition 90.9% 
5.  Respiratory support: noninvasive 
ventilation, oximetry assessment, and use 
of Cough Assist 
45.4% 
6.  Polypharmacy, comorbidities, and follow-
up 
90.9% 
7.  Augmentative and alternative 
communication 
45.4% 
8.  Mobility, transfer, and positioning 
(pressure scar prevention and use of 
technical aids for mobility /transfers) 
72.7% 
9.  Emergency situations X 
10.  Caregiver self-care 69% 
Note. ALS = amyotrophic lateral sclerosis; X= none question was allotted to this module 
 
6.5 Discussion: 
The uncertain timeframe progression and long-term care required for the ALS management 
make that the admission of these patients in acute hospitals a non-sustainable option. 
Moreover, most of the nursing home facilities in our country have no specialized health 
staff to supply all the ALS patient needs. Initiatives that improve the care management at 
home can be an alternative solution.  
An important part of the clinical management is identifying and following-up the caregiver 
capacity to perform self-care and care to the patient (149).  This follow-up may include 
home evaluations and provide information about the disease progression, drug 
interactions, and identification of a contact person in the community health center, to 
quickly manage complications/exacerbation of the clinical status or emergencies, including 
back-up plan for caregiver incapacity.  
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Education and training of the caregiver facilitate the adherence to the proposed health-
care plan favoring greater clinical benefits (150). The involvement of a specialized palliative 
care staff can improve the family satisfaction, symptom management, and decreases costs 
(151).  
 In this study, we identified familiar caregivers with active productive life and/or with family 
responsibilities such as children care. For those who are retired and/or older caregivers, 
the physical impairments make these tasks harder. The written test showed us that there 
are areas where caregivers still need more support even after the Training Program, 
namely, respiratory support and augmentative and alternative communication. These 
findings are aligned with previous studies about stressors in caregivers of terminal diseases 
(152). The total functional disability in ALS has the potential to produce significant financial 
constraints, because the family members responsible for the patients care needs to leave 
their jobs or invest personal financial resources. These families may develop high levels of 
stress, which can compromise the delivery of a proper health-care leading to 
hospitalization of ALS patients. 
Our study focused on assessing the practical aspects for implementing Training Program 
for ALS caregivers, such as predicted cost, main barriers for participation and learning of 
target skills from an appropriate intensity and duration of the Training Program through 
theoretical and hand-on approaches. We identified an excellent level of participation by 
the ALS caregivers as well as a very good outcome in the assessment of learning.  
The main challenge identified on the first Training Program was related to the rate of 
participation per day, which was slightly unstable. A further addendum to the project 
allowed more flexibility to caregivers to participate more effectively, and participants 
received a certificate of completion for an attendance of 75%.  
The limitations to our pilot study are related to the lack of internal or external validity as 
well as absence of size effect analyses. However, we believe, to the best of our knowledge, 
that this is the first feasibility study which describes Training Program for ALS caregivers. It 






A simple delivery of technical aids to address the functional disability of the patient does 
not has by itself the capacity to reduce the stress of all social and emotional losses added 
to functional impairments throughout the disease progression. The training of caregivers 
of patients with chronic progressive and disabling disease must be part of the clinical 
management. This type of initiative has the potential to be replicated or adapted in other 
countries. Further studies must validate the effectiveness of the Training Program and 
should assess its impact on the proper utilization of health care services and hospital 
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Chapter 7:  
Disease Progression in Low resources 
settings: 
Preliminaries results from studies with 




This chapter presents results of 2 works performed in South Africa which appointed a 
potential impact of the low resource settings on the disease progression. The first work 
demonstrated the inconsistencies identified in the ALSFRS-R score during performance of 
a longitudinal study about the clinical course of MND/ALS in the Western Cape Province – 
South Africa. The second work presents preliminaries outcomes from a data comparison 





7. Disease Progression in Low resources settings - Preliminaries results from 
studies with South African ALS patients  
 
7.1. Effects of socio-economic and cultural factors on the ALSFRS-R in South 
African ALS patients: A pilot study 
 
7.1.1 Introduction: 
The gold standard tool currently used worldwide for measurement of ALS functionality and 
disease progression is the ALSFRS-R. The respiratory sub-scores on the ALSFRS-R assess the 
respiratory functionality through questions 10 (dyspnea), 11 (orthopnea) and 12 
(respiratory insufficiency). The Item 12 of ALSFRS-R assesses the respiratory insufficiency 
based on actual non-invasive ventilation (NIV) usage by the patient. In low and middle-
income countries, such as South Africa, NIV usage is influenced by availability of equipment, 
cultural considerations, and access to healthcare, which is dependent on socioeconomic 
circumstance. This may lead that the item 12 scores reflect more these external factors 
rather than the respiratory insufficiency, and therefore, can mask the decline of the 
ALSFRS-R in a setting where the Non-Invasive Ventilation is not used often. 
7.1.2 Objective: 
We aimed to investigate the presence of a potential bias – “a false higher total score” - due 
to lack of provision in ALSFRS-R related to “no use of NIV”. 
7.1.3 Methods:  
We carried out a pilot study with 103 ALS patients whom are part of a longitudinal study in 
the Western Cape Province, South Africa. Inclusion and exclusion criteria are summarized 
in the table 19. We analyzed a sub-group of patients (n=37) who presented with the 
following criteria: (1) % FVC < 80% of predicted with or without respiratory symptoms or 
(2) % FVC > 80% of predicted but with respiratory symptoms as assessed by Q10 and Q11 
on the ALSFRS-R. We compared both of those criteria to Non-Invasive Ventilation usage 




Table 19. Inclusion and Exclusion criteria  
 
7.1.4 Results: 
Our sample (n=37) had 26 males, 31 spinal-onset, with mean age at diagnosis of 56.6 years 
(±10.6), and mean disease duration at inclusion of study:  16.5± 12.7 months. The mean 
ALSFRS-R (±SD) was 35.7 ± 7.45 at T0, 29.4± 9.35 at T1 (up 6 months), and 27.4± 9.78 at T2 
(up 12 months). Clinical and demographics features are summarized in Table 20. The 
percentage of patients with FVC < 80% was 83.8% at T0, 86.7% at T1, and 94.1% at T2. 
Dyspnea (Q10 – score < 4) was present in 56.8% of patients at T0, 75.7% at T1 and 81.0% 
at T2, while orthopnea (Q11 score < 4) was present in 18.9% at T0, 48.6% at T1, and 61.9% 
at T2. Twenty-two patients (59.45%) had FVC < 80% and respiratory symptoms in Q10 and 
Q11 at T0, and maintained this situation at T1, but did not start NIV (Q12 score = 4) at T1.  
Only 5 patients (13.5%) were using NIV (Q12 score < 4) at T1. At T2, 21 patients were alive, 
4 patients did not need NIV, and 6 (28.6%) patients were using NIV (Q12 score < 4). Eleven 
patients met criteria for starting NIV but did not do so (Figure 21).  
  
Inclusion Criteria 
Age between 18 or older 
Diagnosis of possible, probable or definitive according the revised El Escorial criteria for 
ALS (with Awaji electrodiagnostic criteria) 
Diagnosis of PLS, PMA or Progressive Bulbar Palsy 
Exclusion criteria 
Residing beyond the borders of the Western Cape Province of South Africa (i.e. patients 
referred for consultation from neighboring provinces or countries 
Presence of a different underlying neurological disorder complicating the assessment 
and diagnosis 
Inability to attend follow-up visits at the Division of Neurology, Tygerberg Hospital 
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Table 20. Results 
 
7.1.5 Discussion:  
As ALSFRS-R does not make provision for “non-use of NIV” in patients with respiratory 
impairment, a score of 4 on the Q12 is assigned despite the presence of clear respiratory 
impairment. This may lead to a discrepancy between Q12 and the other items assessing 
respiratory function on the ALSFRS-R, and subsequent false high scores on the respiratory 
sub-scale of the ALSFRS-R. Ultimately, this may lead to plateauing of the total ALSFRS-R 
score, which could potentially introduce bias on the total score in cohort studies or clinical 
trials in lower and middle-income countries. 
7.1.6 Conclusions:  
Researchers should be aware of the shortcomings of the ALSFRS-R with respect to the 
evaluation of respiratory function. Our findings suggest that ALSFRS-R should be 
restructured or adapted for use in situations where cultural or socioeconomic factors 
influence the management of respiratory failure in ALS patients.  
Based on the Poster presentation: 
Braga, AC: Henning, F. Effects of socio-economic and cultural factors on the ALSFRS-R in South 
African ALS patients: A pilot study. In 28th ALS international symposium in Boston, USA (2017). 
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal. Volume 18, 2017 - Issue 
sup2: Abstracts from the 28th International Symposium on ALS/MND(A. Braga & Hennig, 2017) 
  
 
Results (37 ALS patients), mean (± S.D) 
Male/female ratio 26/9 
Age at Study 56.6 years (±10.6) 




 At entry (T0)  At 6 months(T2) At 12 months (T2)  
ALSFRS-R total score 35.7 ± 7.45 29.4± 9.35 27.4± 9.78 
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7.2 Comparative study between Portuguese and South African ALS 
populations: Preliminaries results 
 
7.2.1 Introduction: 
Nowadays, we can identify epidemiologic data of ALS from Europe, North America (i.e. 
United States and Canada), Asia and the Pacific region. There is no published information 
about ALS from the African Continent. 
This brief report presents preliminary data from ALS patient in South Africa unknown up to 
now. Those South African data were compared with a Portuguese population data 
regarding the socio-demographic characteristics and clinical follow up. It is expected that 
this report comes up a small and original contribute about the presence of ALS in African 
Continent. 
7.2.2 Objective: 
The objective in this study was not compare different outcomes but verify similarities and 
differences between a very well defined European ALS population and a never studied 
African ALS population. It is expectable that we identify discrepancies between these two 
populations. 
7.2.3 Material and methods: 
This is a prospective descriptive exploratory study aiming to compare data between 
Portuguese and South African ALS populations. Data from South African sample were part 
of a longitudinal study about the incidence and clinic course of MND/ALS in Western Cape 
Province, which still is ongoing in the Division of Neurology of the Tygerberg Academic 
Hospital (TBH) and Faculty of Medicine and Health Sciences (FMHS) in Stellenbosch 
University. This study has been conducted by Dr. Franclo Henning. The deadline for 
completion of this study is 2020. Data from Portuguese sample came from a study 
performed to evaluate the role of exercise on disease progression held at Neuromuscular 
Unit – Neurology Service – Centro Hospitalar Lisboa Norte, which was presented in chapter 
4 of this Thesis. 
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The data analysed in both countries were related to: age of symptom onset and/or ALS 
diagnosis, ALSFRS-R score at diagnosis, survival up to NIV and PEG, gender distributions, 
type of onset, survival on the first 12 months from diagnosis. In addition, it is included data 
of risk factors and cause of deaths for ALS from South Africa. 
The Portuguese sample included medical records review of 48 ALS patients registered in 
the Neuromuscular Unit – Neurology Service – Centro Hospitalar Lisboa Norte – in Lisbon. 
This Portuguese neuromuscular unit was a specialized ALS Center, which included a Senior 
Neurologist, a Rehabilitation Physician, a Physiotherapist, a Social Worker, Speech and 
Language Therapist, and an Occupational Therapist. The follow up of ALS patient is done 
each three months and there is a regular dedicated ALS Neurology consultation twice per 
week. 
The regular examinations include: functional assessment each 3 months with the revised ALS 
Functional Rating Scale (ALSFRS-R), the need for Non-Invasive Ventilation (NIV) support which 
is assessed based on the results of percutaneous nocturnal pulsed oximetry, respiratory 
function test and abnormal phrenic nerve response as well as the presence of respiratory 
symptoms (in according with respiratory sub-score of the Amyotrophic Lateral Sclerosis 
Functional Scale-Revised [R of ALSFRS-R] < 12), and sometimes daytime blood gases and 
SNIP. Nocturnal pulse oximetry (NPO) is measured continuously during sleep, by fingertip 
infra-red pulse oximeter. Mean oxygen saturation (SpO2mean) overnight and Time of 
SatO2<90 (percentage of time which SpO2 recording was below 90%) data are collected. 
Regarding the Respiratory function tests (RFT) it is used %FVC and slow vital capacity, MIP, 
MEP, and P0.1. All these examinations are part of the usual routine care at the Portuguese 
unit. The clinical follow up with Allied health professionals is done in according with medical 
referral. 
Data from South African sample were collected at the Neuromuscular Unit in Division of 
Neurology – Tygerberg Academic Hospital at Cape Town; Western Cape Province. It was 
included a cohort of 67 ALS/MND patients with follow up until 12 months. Study data were 
collected and managed using REDCap electronic data capture tools hosted at Stellenbosch 
University (153). REDCap (Research Electronic Data Capture) is a secure, web-based 
application designed to support data capture for research studies, providing: 1) an intuitive 
interface for validated data entry; 2) audit trails for tracking data manipulation and export 
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procedures; 3) automated export procedures for seamless data downloads to common 
statistical packages; and 4) procedures for importing data from external sources. Clinical 
records collected during the consultations are inserted in this database and only authorized 
personal can access the data. The period of data collection in this study in South Africa was 
18 months.  
The South African neuromuscular unit is compounded of an MND/ALS specialized Senior 
Neurologist, who is the responsible for a dedicated MND/ALS clinic. This clinic also provide 
consultation with Allied health professionals (Occupational Therapist, Speech and 
Language Therapist, Physiotherapist and Dietitian). The follow up of MND/ALS patient is 
done each three months and a dedicated Neurology consultation occurs once per week. 
The regular examinations include: assessment with the revised ALS Functional Rating Scale 
(ALSFRS-R), and the need for Non-Invasive Ventilation (NIV) is assessed based on the results 
in Respiratory function tests: Functional Vital Capacity (FVC) – % predicted, Maximum 
Inspiratory pressure (MIP), Maximum Expiratory Pressure (MEP), and Sniff nasal as well as 
the presence of respiratory symptoms reported during clinical assessment. 
Statistical Analysis: 
It was performed the Kolmogorov-Smirnov test to analyze the normality of the sample. 
Differences between two groups were compared using t-test or a Mann-Whitney test as 
appropriate for the continuous variables (age at onset, disease duration from onset, 
evolution up to NIV and up to PEG since the diagnosis, and functionality by ALSFRS-R) and 
categorical variables (gender, site of onset, NIV use, PEG use and survival up to 12 months 
from the diagnosis). Significance was set at p≤ 0.05. Statistical analysis was carried out in 
IBM SPSS Statistics 22 (Chicago, IL). 
7.2.4 Results:  
It was analysed data from 115 patients in total, n= 48 in Portugal and n=67 in South Africa. 
The gender distribution and region of onset were very similar between countries. Most 
patients were male, with the spinal onset. The demographic and clinical characteristics are 
summarized in Table 21. The survival within the first 12 months after diagnosis was 
significantly different between ALS patient’s populations (p=0.005) (see table 22) as 
expected.  A Spearman’s correlation analyses identified that survival in the 12 months from 
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diagnosis in Portugal was correlated to NIV use (Rho= - 0.32, p=0.024), gender (Rho=0.30, 
p=0.042) and type of onset (Rho= 0.38, p=0.007), but South African survival in the same 
time frame did not show any significant relationship with same variables. The cause of 
death on the first 12 months are detailed in the table 23.  
 
Table 21: Demographic and clinical characteristics of groups  
 PT (N=48) Range SA(N=67) Range p-value 
Male¥ 32 (66.7%) - 45 (67.2%) - 1.0 
Age of Onset* 62.02 (±12.44) 34 - 86 58.9(±12.08) 34 - 81 0.18 
Type of Onset ratio¥ 
(Sp/Bb/Resp)  
77.1% Sp (37) 
22.9% Bb (11) 
- 79.1% Sp (53), 
19.4% Bb (13) 
 1.5% (1) Respir. 
- 1.0 
Disease duration  
from onset(months)* 
11.5 (±7.9) 0.40 – 33.6 13.57(± 9.0) 3 - 47 0.20 
Evolution up to NIV 
(months)  
7.30(±8.04) 0.13– 31.13 8.1(±6.3) 2.27-21.33 0.78 
Evolution up to PEG 
(months)* 
25.0 (±13.4) 5.67-55.30 3.14 (±2.7) 0.23 – 6.30 <0.001 
ALSFRS – R Diagnosis (mean ±S. D) 
ALSFRS-R*Total score 42.02(±4.27) 30 - 47 37.15(±7.13) 15 - 47 <0.001 
Respiratory Function Test (mean ±S. D) 
Forced vital Capacity 
(FVC)% predic* 
89.4(±23.6) 32 - 166 72.6(±23.5) 23 - 123 0.001 
NIV patients up to 12 months from diagnosis 
Ratio Yes/No NIV use¥ 70.8% Yes 
29.2% No 
- 21.4% Yes 
78.6% No 
 <0.001 
PEG patients up to 12 months from diagnosis 
Ratio Yes/No PEG use¥ 29.2% Yes 
70.8% No 
 9.5% Yes 
90.5% No 
 0.09 
Legends: Sp – Spinal, Bb – Bulbar, Resp.- Respiratory, NIV – Non-Invasive Ventilation, PEG – Percutaneous 




Table 22: Survival up to 12 months PT vs SA (Mann-Whitney Test) * p=0.005 
 PT (N=48) SA(N=67) 
Dead between diagnosis and 12 months 2 (4.2%) 18(26.9%) 
Alive up to 12 months after diagnosis 46 (95.8%) 24 (35.8%) 
Loss of follow up after diagnosis --- 17 (25.4%) 
Loss of follow up after 2nd visit from diagnosis 
(6 months) 
--- 8 (11.9%) 




Table 23. Cause of Death up to 12 months 
from diagnosis in SA (N=18) 
Unknown 16.7% 
Respiratory failure 61.1% 





Regarding the follow up of ALS patients by Allied Health Professionals, the Portuguese 
sample had a full follow up by Physiotherapist (PT), Occupational Therapist (OT) and Speech 
and Language Therapist (SLT) in a Rehabilitation and/or Neurology service in the Centro 
Hospitalar Lisboa Norte, at Lisbon. Whenever necessary, ALS patients were referred for 
others Rehabilitation services in their residence area. In this study it was not identified data 
about Allied Health Professional (AHP)’s follow-up for ALS patients at Tygerberg Hospital, 
except for eventual attending on the MND clinic which happened each three months. This 
clinic started to work at 2015, and ALS patients receive orientations from Allied Health 
Professionals to manage the consequences of disease progression and follow up from a 
Senior Neurologist. There are no AHP treatment sessions during this clinical follow up. 
During the disease progression ALS patients cope with additional problems beyond the 
mobility, such as: respiratory failure and loss of weight/swallowing problems, and a few 
cases with behaviour changes also. The clinical management for feeding problems were 
significantly different between countries regarding the timing to introduce the PEG use, 
but regarding the respiratory management there was no difference at the timing to start 
NIV usage. (See table 21).  The difference found was related to the number of patients who 
had started NIV usage.  
 We found that 70.8% Portuguese patients were using NIV up to 12 months from diagnosis, 
while only 21.4% of South African patients started NIV in the same period. Regarding the 
PEG placement, we found that 29, 2% of Portuguese were submitted to PEG procedure, 
while only 9.5 % of South African patients performed this procedure in the period of 12 





In African continent we have scarce information about MND/ALS patients, exception made 
for those countries that present organized health systems as South Africa. Data about the 
course of motor neuron disorders hails mainly from North America and Europe - regions 
with predominantly Caucasian populations. None studies have been reported about MND 
in population groups of African or mixed origin the sub-Saharan region and South Africa 
until now. 
 A recent systematic review (154) about the global epidemiology of ALS published on 2013 
whose the number of studies by region included: 25 in Europe (11 in Italy), 5 in North 
America, 6 in Asia and the Pacific, and 1 in Uruguay (South America). In all that studies, 
most of them referred that the mean ± standard deviation (SD) age for ALS disease onset 
was 61.8 ± 3.8 years (range 54–67); mean ± SD age for ALS diagnosis was 64.4 ± 2.9 years 
(range 58–68), and the mean ± SD diagnostic delay was 12.6 ± 2.6 months (range 8.6–16.8). 
In this comparative study, the mean age for ALS onset identified in our findings in the 
Portuguese sample was like the systematic review, but different for South African 
population, which presented a younger affected population. Additionally, in both 
countries, it was found a range of age disease onset wider (30' - 80' years old), which is 
different of the findings in the aforementioned Systematic review. Our finding is closer to 
the Chinese ALS population, which are younger also (55.07 ±10.74;33-80) (155).  A wider 
range of age of ALS onset (30’s – 80’s) is an interesting finding whether we consider the life 
expectancy for both populations. In South Africa the life expectancy at birth for 2017 was 
estimated in 61.2 years for males and 66.7 years for females. Although in South Africa the 
life expectancy was around 60’s years, we identified patients with age onset around the 
80’s. However, it might be affected by the sample size also. This study analysed an 
ALS/MND population in Western Cape Province – South Africa that contains only 11.5 % of 
South Africa population (156) , and a higher development level with a health system with 
more available resources. Those can be considered confounding factors. 
Comparatively with South Africa, the life expectancy at birth in Portugal is higher: 76.2 for 
males, and 82.9 for females in according with latest data published by Index Mundi in 2017 
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(157). The population distribution estimates by ethnic group and age in South Africa is 
demonstrated in the table 24. 




Male  Female  Total  
Number  % distribution 
of males  
Number  % distribution  
of females  
Number  % 
distribution 
of total  
African  22 311 400  80.8  23 345 000  80.8  45 656 400  80.8  
Coloured  2 403 400 8.7 2 559 500  8.9  4 962 900  8.8  
Indian/Asian  719 300  2.6  689 800  2.4  1 409 100  2.5  
White  2 186 500  7.9  2 307 100  8.0 4 493 500  8.0  
Total  27 620 600  100,0  28 901 400  100,0  56 521 900  100,0 
 
The functionality (ALSFRS-R) and the Forced vital capacity (%FVC predicted) at the diagnosis 
moment were significant different between countries(p=0.001), although the range of age 
of onset were similar. In South Africa the patients presented a lower level of functionality 
and %FVC predicted compared to Portugal, suggesting a more aggressive disease 
progression.  
We identified a higher number of patients submitted to PEG up to 12 months from 
diagnosis in Portugal than SA, but the evolution up to use of PEG was shorter in SA than 
Portugal. This finding suggests that in SA the patients were in a more advanced stage of the 
disease than Portugal at the diagnosis moment and can be confirmed by the lower ALSFRS-
R and FVC. Regarding the Non-invasive ventilation patients, it was identified a higher 
number in Portugal than SA (see table 21). However, this can be potentially related to 
healthcare access and/or lack of official policies for respiratory care in SA. The Survival in 
SA was shorter than in Portugal up to first 12 months in male patients with spinal onset 
without NIV use. In Portugal we found a shorter survival only in 2 patients under NIV, who 
were female and bulbar patients, whom in according with the current literature, present a 
worse prognosis. As describe previously, most of cause of death in SA cohort were related 
to respiratory problems. 
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All these factors suggest that in the SA cohort the disease presented a disease evolution 
more aggressive than Portugal. However, it is not possible affirm with certainty whether 
this faster progression in SA was related or not to other confounding factors like other co-
morbidities, social conditions and health care access, whom could have affected the 
diagnosis timing and the NIV access. Further studies need be addressed to clarify this point 
of view. 
In Portugal, the healthcare policy for patients that need respiratory support at home are 
very well defined in documents issued by the National Health System, which are based on 
the national consensus from experts in the field with scientific support of international 
guidelines (158). Patients have access to respiratory support at home based on a clinical 
report from a specialist consultant from the National Health System. 
Regarding the clinical management in South African sample, it was identified no guidelines 
or official documents from National Department of Health related to prescription of 
respiratory support at home. 
The data (empirics) that describing the main obstacles to start the NIV usage were 
identified from healthcare professionals in the clinical practice and from personal reports 
of patients. That can be described as: “…patients and families often are not aware of 
benefits of NIV usage…”, “…most patients are dependent on MND/ALS association and 
others charity associations to obtain portable ventilators…”, “… NIV often is introduced at 
late stage due to lack of specialized ALS care out of limits of big cities that would ensure 
early identification of the respiratory failure…”.  
Social factors like power supply for patients in poor communities and /or cultural factors 
exclude those patients from the NIV use, and the financial costs often limits the access to 
basic systems which do not include humidification and different interfaces that would 
improve the NIV compliancy. All these factors contrast with the reality described in the 
trials performed in more developed countries and must be object of further analyses.  
A study published by Braga (150) in 2015 refers that 90% of ALS patients in the Portuguese 
Neuromuscular unit in Lisbon were referred for Medicine and Rehabilitation Service and 
received technical aids and respiratory support. However, this study analysed regionals 
differences between ALS follow up in Portugal and cannot be considered representative of 
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all ALS Portuguese population. Regarding the role of exercise in the rehabilitation context, 
there is not data about the clinical approach of Physiotherapist in ALS/MND patients 
published in the African continent. 
7.2.6 Conclusions: 
A recent systematic review published in 2014 (159) about the Epidemiology of 
neurodegenerative diseases in sub-Saharan Africa(SSA) concluded that the body of 
literature on neurodegenerative disorders in SSA is large about dementia and HIV-related 
neurocognitive disorders but limited for other neurodegenerative disorders. Shortcomings 
are related to few population-based studies, heterogeneous diagnostic criteria and uneven 
representation of countries on the continent. There are important knowledge gaps that 
need urgent action, to prepare the sub-continent for the anticipated local surge in 
neurodegenerative diseases. The work from Quansah and colleagues (160) in Sub-Saharan 
Africa shows that the published literature about MNDs is based in populations ‘studies, and 
describes only disease prevalence, genetic factors, and other risk factors. Its findings are 
indicators that the amount of research evidence on MNDs in this region of Africa is scanty; 
and suggested that molecular and genetics-based studies are particularly lacking. 
Neurodegenerative disorders research is leaded by South Africa with a network involving 
the USA, the UK, as well as African countries such Zambia. The chief field that emerged was 
on patient and hereditary as well as treatment. Public health policies were lacking fields in 
research whereas prevalence is estimated to be important in every country (161).We hope 
this report with preliminaries outcomes can contribute to launch some starting points for 


























8. General Discussion and Conclusions: 
 
8.1 Introduction:  
 
Amyotrophic Lateral Sclerosis (ALS) belongs to a wider group of disorders known as motor 
neuron diseases, which are caused by gradual degeneration and death of motor neurons. 
These motor neurons initiate and provide vital communication links between the brain and 
the voluntary muscles. The disease starts in an unsymmetrical mode and regardless of 
where the symptoms first appear, muscle weakness and atrophy spread to other parts of 
the body as the disease progresses. Individuals may develop problems with moving, 
swallowing (dysphagia), speaking or forming words (dysarthria), and breathing (dyspnea), 
until the individual lose the total control of the body movements. Despite no effective 
treatment, the clinical management of the disease evolved drastically in the last years. 
Supportive care is best provided by multidisciplinary teams of health care professionals, 
and Physiotherapy can enhance an individual’s independence and safety throughout the 
course of ALS using special equipment and recommendations of exercises programs 
without overworking muscles, which beyond improvement on the cardiovascular system 
may also help to fight fatigue and depression. 
The cardiovascular benefits from an aerobic exercise program was one of the main findings 
from this study. In addition, we tested positively the feasibility to perform a controlled 
home-exercise protocol in ALS patients by using modern monitoring facilities. A number of 
further results were considered relevant for our work, in particular the importance of NIV 
device settings adaptation over disease progression, teaching home management of ALS 
patients for nonprofessional caregivers, disease-care in non-developed countries and its 






8.2. The contribution of this thesis for the role of exercise on the disease 
progression: 
 
The controversy about exercise in ALS is a long-standing issue, not solved by the few studies 
available. While exercise is seen as a powerful therapy, it can also bring risks related to 
progressive neuronal degeneration, ageing, and the possible presence of other co-
morbidities. In ALS patients, weakness due to neuronal loss and physical deconditioning 
(loss of muscle performance) from inactivity are associated. Immobility can cause several 
muscle-skeletal complications, as joint tightness and contractures progressing to pain.  
Physical exercise has been suggested to promote growth factor delivery in experimental 
animal models of ALS. However, the aerobic exercise is understudied in ALS patients due 
the suspicious that the exercise could be harmful for this population. Meeting the 
recommendations from the last Cochrane review about therapeutic exercise in ALS, we 
decided to study the impact of aerobic exercise in ALS progression.  
 We hypothesized that aerobic exercise could contribute for a potential delay in the disease 
progression. Additionally, we decided it would be important to analyze the aerobic capacity 
performance before and after the protocol.  
In our study, we identified a delay of 5.7% on the functional decline favoring the 
intervention group (effect size d= -0.26). In the intervention group VO2 peak remained 
stable as compared with 46% decrease in the control group. These results reinforce the 
positive outcome described in previous (162) and more recent publications (85), which 
supports the concept that physical activity is not a risk factor for ALS progression, and may 
slow functional decline.  
The preservation of the VO2peak throughout study time period is a relevant finding that is 
coherent with Mezzani and colleagues results (82), who showed that the reduced 
peripheral O2 utilization is consistent with deconditioning as the main cause of impaired 
exercise capacity in this population. 
Lanfranconi et al (92) study evaluated the muscle oxidative function during the exercise 
using near infrared spectroscopy (NIRS) and CPET. They suggested that “the clinical 
evaluation alone can hardly discriminate the real exercise tolerance otherwise measurable 
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by CPET: some ALS patients considered “inefficient” at the ALSFRS-R showed a still residual 
capacity from the VO2peak point of view”. Our results agree with the authors. 
The sustained aerobic capacity in the controlled exercise group compared to standard care 
group allow us to affirm that the aerobic exercise is safe and provide benefits for ALS 
patients whether a controlled intensity and closer specialized supervision are present. Our 
explorative trial showed a very high statistical power and can be considered conclusive. 
Regarding a possible effect from aerobic exercise on the neuroprotection effect, as 
suggested in the previous study of our team (89), remain unexplained and must be focus 
of a future longitudinal study. 
The main limitations and concerns that can arise during this type of work are related to 
dropouts or decreased motivation of some patients to cooperate due to fast progression. 
The unpredictability of the disease and the extensive and expensive nature of the costs to 
evaluate biomarkers linked to functional outcomes, sometimes, also can compromise 
outcome analysis. Because this, the use of multicentric trials can be a more suitable choice 
to overcome these limitations.  
We believe that our findings can support future therapeutic approaches and help to 
demystify the belief that the exercise can be harmful for ALS patients.  
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8.3 The contribution of this Thesis for the use of telemedicine to monitoring 
rehabilitation programs for ALS patients.  
 
There is a growing interest on the use of telemedicine for supporting patients, including 
those requiring rehabilitative services which can help to manage their condition (163).  
As we describe previously in the Chapter 4, the level of suitable physical effort that ALS 
patients may perform, without a specialized supervision, is a hard task. Nevertheless, the 
difficult to access an interdisciplinary care in community-based settings is a reality for ALS 
patients in several countries. Some of the barriers to access ALS centers are related to long 
commute to central hospitals and the probable need of a caregiver to help them during 
dislocations. Eventually, patients often choose to abandon the physiotherapy follow up. All 
these concerns lead us to assess the feasibility to delivery an individualized aerobic exercise 
program monitored through wireless device which could address this issue. 
The early detection of overtraining as well as the prevention of shortfalls on care should be 
part of the clinical management. A physician-centered clinical management model is not 
sustainable for critical patient as in Amyotrophic lateral sclerosis (ALS). The Tele-
rehabilitation already has been proposed (163-165) as a health service option that may 
improve exercise-related outcomes, ensuring patient safety during exercise and facilitate 
the access to rehabilitation interventions in other clinical conditions. 
 Moreover, it has the potential to engaging local and community-based services with the 
specialized centers letting the clinical decision-making process faster and closer. It should 
be explored in a context of collaborative self-management (166) and perceived as a 
complementary means to maintain individuals in their own community, or as an alternative 
to conventional hospital outpatient and physicians visits (167) . 
Although some controversies issues arise, like storage and protection of data, accessibility, 
financial investment, health staff training and a potential lack of humanization on the 
patient-healthcare professional relationship, we can suggest that our findings may provide 
substantial improvements to accessibility of rehabilitations programs. 
The main limitations in our study are related to potential selection bias, small sample and 
an exploratory nature of study meaning that a further validation is necessary on a larger 
144 
 
trial before being generalized. Despite of these limitations, the feasibility outcome for the 




8.4: The contribution of this Thesis for the Management of Respiratory Failure 
with Non-Invasive Ventilation:  
  
Evidence from several retrospective and some prospective studies indicated that NIV may 
be associated with improvement in survival (6), and the use of NIV in ALS has greatly 
increased. Unfortunately, the interaction between patient and ventilator is frequently 
suboptimal and that patient-ventilator asynchrony is common. Our findings indicated the 
need of a closer collaboration between the patient and clinician regarding to set up for 
respiratory parameters of NIV to reach all the benefits on the symptomatic management 
for the respiratory failure in ALS patients. 
 In our study presented in sub-chapter 5.3, we hypothesized whether the ventilation 
settings and compliancy data joined to respiratory function measurements would have 
influence on the functional decline as well as on the survival in ventilated ALS patients. We 
analyzed a set of data recorded from the software used in the Non-invasive ventilators, 
measurements from Nocturnal pulse oximetry and respiratory function tests in a 
prognostic model to identifying predictors of functional decline and survival in a cohort of 
ventilated patients. 
 We identified parameters of Non-invasive ventilation (IPAP, IS, rT, and BR back-up), 
compliancy data (%of spontaneous cycling, I/E ratio, nº of hours of use/day and the mean 
BR) and Nocturnal pulse oximetry data (SpO2mean) as predictors of functional decline, and 
it suggests that the variables affecting the respiratory comfort of patient are indeed a 
prerequisite to a better NIV compliance and affects the ALS survival. This was the first study 
which analyzed the ventilators settings as survival predictive factor. 
The modern technology has provided portable mechanical ventilators with very sensitive 
algorithms, which allow detecting a large range of respiratory symptoms-related variables. 
However, as cited by Kallet and colleagues, 2011 (143) “…while the act of breathing is 
mechanical and quantifiable, it is also a sensory experience upon dependent on the 
individual.”   
 The human being has the capacity to identify unique breath-related sensations that 
sometimes cannot be detected by the equipment, and in this point, a trustable relationship 
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between the clinician and patient, respecting and validating theirs limits and complaints 
may have a potential impact on the NIV compliancy and on the survival of an ALS patient. 
Compliance plays a relevant role on the respiratory support. An optimized approach which 
avoid a NIV failure and compliance concerns, are the added value of a closer follow up on 
the respiratory insufficiency. Non-Invasive Ventilation can have a modifier role play on 
disease progression whether a rigorous management is achieved and can make the 
difference on the survival in these patients.  
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8.5 The contribution of this Thesis for the understanding on the role of 
caregivers in the management of disease: 
 
Nowadays, the current guidelines about ALS clinical management highlights the role of the 
caregiver and the side effects related to their role during the disease progression. 
In 2005, Vianello and colleagues (121) reported in their study that the use of mechanical 
Insufflation-Exsufflator (MI-E) for clearance of secretions was effective and safely carried 
out by trained nonprofessional caregivers (i.e., patient’s home care attendant and/or 
family members), and emphasizes that the combined use of NIV and MI-E into home 
management of respiratory problems can potentially reduce the need for hospitalization 
and maintains higher quality of life. In 2010, Paganini and colleagues (168) studied the 
burden of care in ALS caregivers and suggest that the patient’s loss of physical functions 
was positively related with caregiver burden, anxiety, and somatic expression of 
depression.  
Based on these premises, it was performed a pilot project, in parallel with this thesis, to 
develop and implementing a home caregivers training program to provide essential care 
skills to manage the disease progression and helping the caregivers to cope with the 
physical and emotional challenges. We aimed to fill the gap and meet the 
recommendations for ALS caregivers and burden of care suggested in the guidelines for 
clinical management in ALS published by European Federation of Neurology Societies 
(EFNS) in 2012.  
The training program was carried out in 2013 and 2014 and reached a total of 77 caregivers 
in Lisbon and Porto. As Oliver and colleagues (149) have suggested “an important part of 
the clinical management is identifying and following up the caregiver capacity to perform 
self-care and ability to provide safe care to the patient”. 
 In this project, we identified an excellent level of participation as well as a very good 
outcome in the assessment of learning (above 70% successful approval), and the aim of 
provide care skills for ALS caregivers based on scientific evidence was achieved.  On the 
other hand, the main limitation factor to participation in the project was the absence of a 
secondary caregiver. Unfortunately, the lack of specialized healthcare professional in 
health community centers still is a potential challenge in the improvement on the quality 
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of life and personal life autonomy for the ALS caregivers in Portugal. Further studies must 
analyze the impact of these initiatives on the quality of life for caregivers and patients, and 
the cost effectiveness for the healthcare system.  
Currently, this training program still is performed by the APELA, and others public health 
services adopted the idea and started adapted training programs for ALS caregivers in cities 
at the countryside of Portugal.  
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8.6 The contribution of this Thesis for the understanding on the disease 
progression in Limited resources setting: 
 
 
In the South African context, the clinical management of ALS suffers from a lack of 
specialized healthcare professionals. The respiratory support to manage respiratory failure 
in ALS faces hard challenges regarding NIV use. This is largely related to unavailability, 
which is dependent on socioeconomic and/or cultural circumstances. We performed two 
exploratory studies aiming to understand the effects of cultural and social environment on 
disease management and progression. The first study investigated the presence of 
potential bias in the respiratory sub-score due to NIV unavailability, which can lead to 
flattening of the ALSFRS-R decline, and thereby resulting in inaccurate assessment of 
disease progression. The second study explored similarities and differences with the 
management of ALS in Lisbon. 
Despite the social and economic development in Europe and USA, ALS patients in South 
Africa potentially share the same personal, social, and healthcare burden. The health 
systems in developed countries potentially might relief the impact of these stressors in the 
ALS patients and their families, but in lower and middle-income countries these stressors 
are a very relevant concern. The lack of a specialized support, underprivileged access to 
healthcare and absence of alternative solutions, which allows a better clinical management 
of the disease, constitutes a worrying reality for the ALS patients and their families in South 
Africa.  More funding is necessary for research, to clarify the policymakers about the 
devastating emotional, social and economic effects that this disease can cause in the 
families. These preliminary results hope inspire other researchers to give more attention 
to the different economic and social contexts in the development of clinical guidelines. We 
suggest studies about alternative solutions that can be applied in low resource settings. 
The main limitations of these studies are their exploratory nature and small samples sizes. 
Future investigations must be performed to confirm these findings.  
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8.7 Prospects for the future: 
 
The research on the potential role of exercise on the ALS has relatively increased last years. 
Previous studies from colleagues in our unit have demonstrated relevant contributions of 
the exercise in ALS. A study from Pinto and colleagues (63)  suggests that the respiratory 
muscle training in early stages of the disease may provide a transitory mild benefit as 
measured on the clinical evaluation and respiratory fatigue tests, and a longer survival 
compared to the control group.  
In this thesis, it was possible to identify a sustained aerobic capacity in the exercise-
controlled group compared to control group, suggesting a clear benefit of the use of CPET 
to tailoring an exercise program for ALS patients. It would be interesting to analyze if the 
aerobic capacity could be related with changes on the Vascular Endothelial Grow Factor as 
suggested previous study in 2014 (89).  
VEGF is one of the critical factors released in the tissues surrounding the small vessels 
during the process of angiogenesis (169). Studies from others neuromuscular diseases 
using low-to moderated-intensity strength and aerobic exercise programs have shown 
beneficial effects like increase of both angiogenesis and neurogenesis processes in regions 
of the brain (170) .  
Previous studies showed that locomotion on a treadmill can increase the density of blood 
vessel and cortical and striatal angiogenesis in the brain (45). 
Recently the use of modern techniques as Near InfraRed Spectroscopy (NIRS) was applied 
to detecting early stages of oxidative deficiency in ALS, disclosing individual impairments in 
the O2 transport and utilization chain during an exercise protocol. NIRS is a non-invasive 
method that allows the monitoring of tissue oxygenation using the principle that near-
infrared light absorption characteristics of hemoglobin (Hb) and myoglobin depend on their 
O2 saturation at different wavelengths (780 and 850 nm, respectively) (171,172). 
Considering the growing interest about the exercise impact as non-pharmacologic therapy 
in ALS in the last years, the understanding of how tailored exercise programs can 
influencing neuroprotection through modulation of neurotrophic factors still need more 
research. Open questions are the impact of exercise on the progressive loss of motor 
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neurons and the impact of exercise on the levels of neuroprotective factors like as VEGF. 
Perhaps, a future study should consider a tailored exercise program VEGF level variation 
and neurophysiologic studies to quantify lower motor neuron pool. Further studies are 
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